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XenobioticCytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57
putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families,
are responsible for the biotransformation of most foreign substances including 70–80% of all drugs in clinical
use. The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and
3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically. Expression of each
CYP is inﬂuenced by a unique combination of mechanisms and factors including genetic polymorphisms,
induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age,
and others. Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for
the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes
termed as poor, intermediate, extensive, and ultrarapid metabolizers. For these CYPs, the evidence for clinical
signiﬁcance regarding adverse drug reactions (ADRs), drug efﬁcacy and dose requirement is rapidly growing.
Polymorphisms in CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4 are generally less predictive, but new data on
CYP3A4 show that predictive variants exist and that additional variants in regulatory genes or in NADPH:
cytochrome P450 oxidoreductase (POR) can have an inﬂuence. Here we review the recent progress on
drug metabolism activity proﬁles, interindividual variability and regulation of expression, and the functional
and clinical impact of genetic variation in drug metabolizing P450s.
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Predicting the fate of a drug in a particular patient and his or her
subsequent response is still a vision and far away from application in
routine clinical practice. Recognizing the sources and understanding
the factors that contribute to the extraordinary pharmacokinetic and
pharmacodynamic variability within and between individuals remains
a challenge of particular importance for drugs with narrow therapeutic
index (Lin, 2007). The cytochromes P450 (CYPs) constitute the major
enzyme family capable of catalyzing the oxidative biotransformation
of most drugs and other lipophilic xenobiotics and are therefore of par-
ticular relevance for clinical pharmacology (Nelson, 2004; Guengerich,
2008; Zanger et al., 2008). In humans 57 putatively functional genes
and 58 pseudogenes are encoded by various gene clusters distributed
over most autosomal chromosomes, in comparison to 108 functional
and 88 pseudogenes in the mouse (Nelson et al., 2004). Most of the
human genes, which are grouped according to their sequence similar-
ity into 18 families and 44 subfamilies (http://drnelson.uthsc.edu/
human.P450.table.html), have speciﬁc endogenous functions including
the biosynthesis of steroid hormones, prostaglandins, bile acids, and
others (Nebert & Russell, 2002). Only about a dozen enzymes belong-
ing to the 1, 2, and 3 CYP-families are responsible for the metabolism
of the majority of drugs and other xenobiotics. Despite the broad and
overlapping substrate speciﬁcities of these enzymes, many drugs are
metabolized at clinically relevant concentrations by one or few en-
zymes only, which limits the important redundancy of the phase I
drug oxidation system. Knowledge of the intrinsic and extrinsic factors
that inﬂuence expression and function of the responsible enzymes is
thus a prerequisite for predicting variable pharmacokinetics and drug
response. While monogenic polymorphisms explain a major part of
the variability for only few enzymes (in particular CYP2D6), most
enzymes are multifactorially controlled including additional polymor-
phisms in regulatory trans-genes and nongenetic host factors including
sex, age, disease, hormonal and diurnal inﬂuences and other factors
(Fig. 1). In this review we cover the CYPs of families 1 to 3 whichFig. 1. Fraction of clinically used drugs metabolized by P450 isoforms and factors inﬂuencin
(Table 3; chemicals and endogenous substrates excluded) were analyzed. Each metabolic
variability factors are indicated by bold type with possible directions of inﬂuence indicated (
of controversial signiﬁcance are shown in parentheses.have been shown to be of major importance for the biotransformation
of drugs. We review the recent progress on drug metabolism activity
proﬁles, interindividual variability and regulation of expression, and
the functional and clinical impact of genetic variation in drug metabo-
lizing P450s, whereas epidemiological studies were only mentioned
occasionally. Our intention was to provide basic knowledge for each
CYP on all these aspects but to focus for the literature survey on the
past ten years. In view of the enormous body of literature we could
not cite all studies and we are aware that it is difﬁcult to provide an en-
tirely objective overview. In this sense, wewould like to apologize to all
authors of studies not mentioned in this review.
2. Factors that inﬂuence
cytochromes P450 expression and function
2.1. Genetic polymorphism
Heritable genetic variation in drug metabolizing enzyme genes
has been studied for over 60 years and many intriguing examples of
the genetic inﬂuence on drug biotransformation have been investi-
gated at great detail and for some of them clinical relevance has
been studied (Meyer, 2004). Interestingly, loss-of-function polymor-
phisms in CYP genes surprisingly often affect splicing and expression,
rather than transcription or protein structure (Sadee et al., 2011).
Gain-of-function variants include copy number variants (CNV) with
an increased number of functional gene copies in CYP2D6 and
CYP2A6 (Johansson & Ingelman-Sundberg, 2008), as well as promoter
variants (e.g. in CYP2B6, CYP2C19) and amino acid variants with in-
creased substrate turnover (e.g. in CYP2B6, CYP2C8). Surprisingly
few polymorphisms affect clearly the substrate selectivity or the in-
ducibility of drug metabolic pathways. Important polymorphisms of
drug metabolizing CYPs with functional and clinical correlates are
summarized in Table 1.
The CYP-speciﬁc drug oxidation phenotype can be determined in
vivo using selective model substrates (Walsky & Obach, 2004; Fuhr etg variability. A total of 248 drug metabolism pathways with known CYP involvement
pathway was only counted once for the major contributing CYP isoform. Important
↑, increased activity; ↓, decreased activity; ↑↓, increased and decreased activity). Factors
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phenotypes. In the case of the classical polymorphisms of the CYP2D6
and CYP2C19 genes, which were discovered by the phenotypic
variation they elicit in drug-treated subjects,“poor metabolizer” (PM)
refers to homozygous or compound heterozygous carriers of alleles
with complete lack of function (null allele); “extensive metabolizer”
(EM) refers to the “normal” phenotype, usually representing the
major proportion of the population; “intermediate” metabolizers (IM)
carry only one normal or functionally deﬁcient allele, resulting in im-
paired drug oxidation capacity; and the “ultrarapid” metabolizer
(UM) phenotype originates from gain-of-function variants (Fig. 2). Se-
vere loss-of-function alleles and functional gene duplications are rare
among CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4, and terms like “slow
metabolizer” and “rapid metabolizer” should here only be used in the
context of phenotypic differences.
The clinical impact of polymorphism in a drug metabolising en-
zyme must be considered within its pharmacological context.
Loss-of-function variants will lead to reduced clearance and increased
plasma concentrations, while gain-of-function variants will lead to
increased clearance and lower drug concentrations. If the drug is
pharmacologically active, this results in increased and decreased
drug effect, respectively, and potentially in drug-related toxicity due
to overdosing. If the drug is metabolically activated (prodrug), the
contrary is to be expected, and the pharmacological activity or toxic-
ity of the metabolite(s) must be considered, as for example in the case
of CYP2D6-dependent morphine formation from codeine. The inﬂu-
ence of genetic polymorphisms on CYP expression and function, as
well as their clinical impact will be discussed for each CYP below.
2.2. Epigenetic inﬂuences on drug metabolism
Some heritable changes in gene function are not based on DNA
sequence variations, and the term epigenetics has been coined to
describe such phenomena. Two important mechanisms are DNAmeth-
ylation and histone protein modiﬁcation. Whereas DNA methylation is
involved in normal cellular control of gene expression, histone modiﬁ-
cation affects the accessibility and transcriptional activity of the chro-
matin within the cell. The term epigenetics further comprises gene
regulatory mechanisms by microRNAs (miRNAs). Epigenetic patterns
are principally reversible and may be tissue-speciﬁc and inﬂuenced
by host factors (sex, age) and environmental factors. The inﬂuence of
epigenetic processes on pharmacologically relevant genes and drug
response is a rather new area of research that has recently been
summarized (Ingelman-Sundberg & Gomez, 2010). A global analysis
of differential gene expression in the human HepG2 hepatoma cell
line following treatment with 5-aza-2′-deoxycytidine to inhibit DNA
methylation and trichostatin A to inhibit histone deacetylation demon-
strated widespread effects on more than 1500 and 500 genes, respec-
tively, including induction of CYP3A genes and other cytochromes
P450, as well as several transcription factors (Dannenberg &
Edenberg, 2006). Examples studied in more detail include primarily
CYP1 genes. CYP1A1 promoter methylation in human lung tissue was
lowest among heavy tobacco smokers and highest in non-smokers,
providing an example of environmental inﬂuence on DNA methylation
patterns (Anttila et al., 2003). In CYP1A2 an inverse correlation
between mRNA and extent of methylation at two CpG sites near the
transcription start site was observed in human liver samples (Ghotbi
et al., 2009). Promoter methylation at multiple CpG sites in the
CYP1B1 gene promoter has been detected and associated with tamoxi-
fen response (Widschwendter et al., 2004) and decreased inducibility
(Beedanagari et al., 2010).
Recent research has also illuminated the impact of miRNAs on
ADME gene expression. A current problem of miRNA information
management relates to the large number of miRNAs, estimated at
over 1000 different molecules per mammalian species and their poor-
ly deﬁned binding speciﬁcities, which allows for a vast number ofpotential miRNA-target gene interactions (Friedman et al., 2009).
Various databases have been developed, using different algorithms
to predict potential binding sites (Laganà et al., 2009; Xiao et al.,
2009; Rieger et al., 2011). However the integration of these datasets
is a difﬁcult task and dedicated software programs, e.g. MIRNA-
DISTILLER, allow the compilation of miRNA predictions from different
databases to facilitate data management (Rieger et al., 2011). Direct
regulation by miRNAs was shown for CYP1B1 and CYP3A4 by
miR-27b (Tsuchiya et al., 2006; Pan et al., 2009), and CYP2E1 by
miR-378 (Mohri et al., 2010). Nuclear receptors are also targets of
miRNAs as shown for the xenosensor pregnane X receptor (PXR,
NR1I2), which was shown to be under control of miR-148a, thereby
inﬂuencing CYP3A4 and CYP2B6 expression levels and the metabo-
lism of xenobiotic drug substrates of these enzymes (Takagi et al.,
2008). Hepatocyte nuclear factor 4 alpha (HNF4α) is regulated by
miR-24 and miR-34a and overexpression of these miRNAs results in
decrease of HNF4α and downregulation of its target genes (Takagi
et al., 2010). The vitamin D receptor (VDR), another transcriptional
regulator of CYP3A4, is also regulated by the CYP3A4-targeting
miR-27b, resulting in an indirect and a direct mechanism for miRNA
regulation of CYP3A4 (Pan et al., 2009). The same miRNA miR-27b
also regulates the peroxisome proliferator-activated receptor PPARγ
(Karbiener et al., 2009; Jennewein et al., 2010) and the liver X recep-
tor (LXR) was shown to be regulated by miR-613 (Ou et al., 2011),
further supporting an important role of miRNAs in hepatic gene
regulation.
Of special interest for pharmacogenetic aspects are SNPs in
miRNAs and miRNA binding sites, as well as miRNA copy number
variations, which may affect their expression and function and thus
inﬂuence target gene expression (Schmeier et al., 2011; Wei et al.,
2012). For example, the dihydrofolate-reductase (DHFR) gene har-
bors a socalled miRSNP in its 3′-UTR, which was found to cause loss
of miR-24 binding leading to DHFR overexpression and association
with methotrexate (MTX) resistance (Bertino et al., 2007; Mishra et
al., 2007). Although the ﬁeld of epigenetic regulation of drug metab-
olism and drug response genes is relatively new, these examples
demonstrate an important impact of miRNAs on ADME gene regula-
tion and potential relevance for drug response.
2.3. Nongenetic host factors
Sex inﬂuences a number of pharmacokinetically important param-
eters including body weight, fat distribution, liver blood ﬂow, as well
as expression of drug metabolizing enzymes and transporters (Beierle
et al., 1999; Gandhi et al., 2004). Sex-speciﬁc expression of cyto-
chromes P450 is common in laboratory animals including rats and
mice and was found shown to be controlled by the different secretion
proﬁles of growth hormone in female versus male animals (Dhir &
Shapiro, 2003; Waxman & Holloway, 2009). In humans the differ-
ences are more subtle and their relevance for drug treatment is a mat-
ter of continuous concern (Gandhi et al., 2004; Schwartz, 2007;
Waxman & Holloway, 2009). A recent genome-wide gene expression
proﬁling study in 112 male and 112 female livers identiﬁed more
than 1300 genes whose mRNA expression was signiﬁcantly affected
by sex, with 75% of them showing higher expression in females
(Zhang et al., 2011). Among these were 40 ADME/ADME-related
genes including CYP1A2, CYP3A4 and CYP7A1 showing female bias,
and CYP3A5, CYP27B1, and UGT2B15 showing male bias. Most clinical
studies indicate that women metabolize drugs more quickly than
men. This is particularly the case for substrates of the major drug me-
tabolizing cytochrome P450, CYP3A4 (e.g. antipyrine, alfentanil,
erythromycin, midazolam, verapamil; Cotreau et al., 2005). Analyses
of CYP3A4 in human liver have indeed shown ~2-fold higher levels
of protein in female compared to male liver tissue (Schmidt et al.,
2001; Wolbold et al., 2003; Lamba et al., 2010; Yang et al., 2010).
This pronounced difference is also apparent on the mRNA level, and
Table 1
Selected genetic polymorphisms of human cytochromes P450 and POR.
CYP allele designationa Key mutation(s)b rs number Location, protein effect Allele frequenciesc Functional effect Clinical correlations
CYP1A1*2C 2454A>G
(rs1048943)
I462V gMAF 0.120
0.0–0.04 Af, AA
0.20–0.26 As
0.03–0.07 Ca
0.18–0.43 Hs
0.17 Pc
↑ Activity (17β-estradiol
and estrone)
↑ Lung cancer risk in Chinese; ↑ breast cancer
risk in Caucasians; ↑ prostate cancer risk
CYP1A2*1C −3860G>A
(rs2069514)
Promoter gMAF 0.188
0.26–0.40 AA, Af
0.21–0.27 As, Pc
0.01–0.08 Ca
0.20–0.30 Hs
↓ Inducibility (smokers) May inﬂuence susceptibility to certain cancers
CYP1A2*1F −163C>A (rs762551) Intron 1 gMAF 0.35 (A>C)
0.5–0.8 all ethnicities
↑ Inducibility (smokers, omeprazole) ↑ Susceptibility to cancer in Caucasians; ↑ oral
clearance olanzapine; possible modiﬁer for risk
of coronary heart disease
CYP1B1*6 142C>G (rs10012);
355G>T
(rs1056827);
4326C>G
(rs1056836)
R48G A119S L432V gMAF 0.32–39
0.5–0.85 AA, Af
0.09–0.13 As
0.23–0.40 Ca
↑ Km, ↓ Vmax (17β-estradiol, recombinant) ↑ Prostate cancer risk for L432V in Asians
CYP2A6*2 1799T>A
(rs1801272)
L160H gMAF 0.013
0.00–0.01 AA, Af
0.00–0.025 As
0.04–0.10 Ca
No activity ↓ Nicotine metabolism & inﬂuence on cigarette
consumption, nicotine dependence, smoking
cessation response; ↑ lung cancer risk in Caucasians;
↓ oral clearance of tegafur
CYP2A6*4A to *4H Recombination CYP2A6 deleted 0.01–0.02 AA
0.05–0.24 As
0.01–0.04 Ca
Null allele
CYP2A6*7 6558T>C
(rs5031016)
I471T gMAF 0.04
0.00 AA, Af
0.06–0.13 As
0.00 Ca
↓ Activity
CYP2A6*9 −48T>G
(rs28399433)
Promoter, TATA-box gMAF 0.13
0.04–0.12 AA, Af
0.16–0.27 As
0.04–0.05 Ca
↓ Activity
CYP2A6*17 5065G>A
(rs28399454)
V365M gMAF 0.025
0.04–0.50 AA, Af
0.00 As
0.00–0.02 Ca
↓ Activity
CYP2B6*4 18053A>G
(rs2279343)
K262R (isolated) gMAF 0.26
0.00 AA, Af
0.05–0.12 As
0.04 Ca
↑ Expression & activity ↑ Drug clearance (bupropion, efavirenz,
cyclophosphamide)
CYP2B6*5 25505C>T
(rs3211371)
R487C gMAF 0.05
0.01–0.04 AA, Af
0.01–0.04 As
0.09–0.12 Ca
↓ Expression & activity Possibly decreased drug clearance
CYP2B6*6 15631G>T
(rs3745274);
18053A>G
(rs2279343)
Q172H K262R gMAF 0.27
0.33–0.5 AA, Af
0.10–0.21 As
0.14–0.27 Ca
0.62 Pc
↓ Expression
↓ Activity (efavirenz, nevirapine)
↑ Activity (cyclophosphamide)
↓ Drug clearance & ↑ adverse events including
treatment discontinuation (efavirenz, nevirapine,
S-methadone)
CYP2B6*18 21011T>C
(rs28399499)
I328T gMAF 0.02
0.04–0.08 AA
0.05–0.12 Af
0.01 Hs
0.00 As, Ca, Pc
↓↓ Expression & activity
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CYP2B6*22 −82T>C
(rs34223104)
Promoter, TATA-box gMAF 0.012
0.00–0.025 AA, Af, As
0.024 Ca, Hs
↑ Expression & activity
↑ Inducibility
Possibly increased drug clearance
CYP2C8*2 11054A>T
(rs11572103)
I269F gMAF 0.039
0.10–0.22 AA, Af
0.00 As, Ca
↓ Activity Controversial clinical effects
CYP2C8*3 2130G>A
(rs11572080);
30411A>G
(rs10509681)
R139K K399R gMAF 0.065
0.00 AA, Af, As
0.65–0.14 Ca, Hs
↓ Activity (paclitaxel)
↑ Activity (antidiabetics)
CYP2C8*4 11041C>G
(rs1058930)
I264M gMAF 0.026
0.00–0.01 AA, Af, As,
Pc
0.03–0.07 Ca, Hs
↓ Activity (paclitaxel)
CYP2C9*2 3608C>T
(rs1799853)
R144C gMAF 0.069
0.00–0.02 AA, Af
0.00–0.02 As, Pc
0.10–0.17
Ca 0.065 Hs
↓ Activity ↓ Drug clearance & ↑ risk of bleeding (anticoagulants
warfarin, acenocoumarol, phenprocoumone);
↓ drug clearance & ↑ adverse events
(sulfonylurea hypoglycemic drugs, NSAIDS);
↓ drug clearance & ↑ adverse events
(sulfonylurea hypoglycemic drugs, NSAIDS)CYP2C9*3 42614A>C
(rs1057910)
I359L gMAF 0.043
0.00–0.01 Af, AA
0.02–0.06 As
0.06 Ca
↓↓ Activity
CYP2C19*2 19154G>A
(rs4244285)
Splicing defect gMAF 0.199
0.10–0.17 AA, Af
0.22–0.32 As, Pc
0.06–0.15 Ca
0.15 Hs
Null allele ↓ Clearance & ↑ efﬁcacy of PPIs in Helicobacter pylori
eradication therapy; ↓ anticoagulation effect of clopidogrel &
↑ cardiovascular events; ↓ clearance & ↑ risk of ADRs for
antidepressants (amitriptypine, citalopram, clomipramine,
moclobemide), antimalarials (proguanil), antifungals
(voriconazole)CYP2C19*3 17948G>A
(rs4986893)
W212X gMAF 0.014
0.00–0.01 Af, Ca, Hs
0.03–0.07 As, Pc
Null allele
CYP2C19*17 −806C>T
(rs12248560)
Promoter gMAF 0.15
0.15–0.27 AA, Af
0.00–0.02 As
0.21–0.25 Ca
↑ Expression & activity ↑ Clearance of PPIs & risk of subtherapeutic
concentrations; ↑ risk of bleeding with clopidogrel
CYP2D6*3 2549delA
(rs35742686)
Frameshift gMAF 0.009
~0.01 all ethnicities
Null allele ↓ Clearance & ↑ risk of ADRs for many antiarrhythmics,
antidepressants, antipsychotics; ↓ metabolic
activation & analgesic effect of opioids (codeine,
dihydrocodeine, oxycodone, tramadol); ↓ metabolic
activation & efﬁcacy of tamoxifen
CYP2D6*4 1846G>A
(rs3892097)
Splicing defect gMAF 0.106
0.01–0.10 AA, Af, As,
Hs
0.15–0.25 Ca
Null allele
CYP2D6*5 Recombination Deletion 0.03–0.06 all
ethnicities
Null allele
CYP2D6*6 1707delT
(rs5030655)
Frameshift gMAF 0.01
~0.01 all ethnicities
Null allele
CYP2D6*10 100C>T (rs1065852) P34S gMAF 0.26
0.08–0.12 AA, Af
0.40–0.70 As
0.02 Ca
↓ Expression & activity
CYP2D6*17 1023C>T
(rs28371706);
2850C>T (rs16947)
T107I R296C gMAF 0.049 (for 1023C>T)
0.14–0.24 Af
0.00 As, Ca
↓ Expression & activity
CYP2D6*41 2988G>A
(rs28371725)
Splicing defect gMAF 0.055
0.01–0.06 Af, As, Pc,
Hs
0.09 Ca
↓ Expression & activity
CYP2D6*Nxn Recombination Copy number variations Up to 0.30 Af, Ar
0.01–0.09 Ca
↑ Expression & activity ↑ Toxicity of opioids
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Table 1 (continued)
CYP allele designationa Key mutation(s)b rs number Location, protein effect Allele frequenciesc Functional effect Clinical correlations
CYP2J2*7 −76G>T (rs890293) SP1-binding to promoter
decreased
gMAF 0.073
0.10–0.17 AA, Af
0.02–0.13 As
0.055–0.08 Ca
↓ Expression & activity No conclusive clinical associations
CYP3A4*1B −392A>G
(rs2740574)
Promoter gMAF 0.20
0.50–0.82 AA, Af
0.00 As
0.03–0.05 Ca, Hs, SA
Probably no effect
on transcription
↑ Prostate cancer disease progression
CYP3A4*22 15389 C>T
(rs35599367)
Intron 6 gMAF 0.021
0.043 AA
0.043 As
0.025–0.08 Ca
↓ Expression & activity ↓ Metabolism of simvastatin & ↑ lipid-lowering
response; ↓ daily-dose requirement for tacrolimus
CYP3A5*3 6986A>G (rs776746) Intron 3, splicing defect gMAF 0.312
0.37 AA
0.12–0.35 Af
0.66–0.75 As, Hs
0.88–0.97 Ca
↓↓ Expression & activity ↓ Metabolism & dose requirements for selected
drugs with a preference for metabolism by CYP3A5
over CYP3A4 (e.g., tacrolimus, saquinavir)
CYP3A5*6 14690A>G
(rs10264272)
Exon 6, K208, splicing
defect
gMAF 0.045
0.15–0.25 Af
0.12 AA
0.00 As, Ca, His
↓↓ Expression & activity
POR*28 31696C>T
(rs1057868)
A503V gMAF 0.287
0.08–0.50 AA, Af
0.38–0.42 As
0.29–0.33 Ca
0.32–0.35 Pc
Various substrate- and CYP-dependent
effects in vitro
↓ Enzyme activity of major CYP enzymes in patients
with rare POR deﬁciency; ↑ CYP3A4 enzyme activity
with midazolam
a According to the CYPallele nomenclature homepage (http://www.cypalleles.ki.se).
b Genomic positions are given with corresponding rs numbers in parentheses.
c gMAF, global allele frequency of the minor allele as reported in the 1000Genome phase 1 genotype data (released May 2011). Selected frequencies of individual ethnicities (AA, African American; Af African; As Asian; Ar, Arab; Ca Cau-
casian; Hs, Hispanic; In, Indian; Pc, Paciﬁc; SA, South American) were compiled from dbSNP (build 137) at http://www.ncbi.nlm.nih.gov/projects/SNP/; from the Allele Frequency Database ALFRED at http://alfred.med.yale.edu/alfred/
index.asp; and from the references cited in the text.
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differences in the order of 20 to 50%. For other CYPs the issue of
sex-biased expression has not been ﬁnally clariﬁed and some contra-
dictory data have been published from different studies, as discussed
below.
Age is a well established inﬂuential factor for drug metabolism
capacity, particularly at the extremes of life, where drug metabolism
capacity appears to be substantially lower. In neonates, this is due
to immaturity of several enzyme systems including cytochromes
P450 (Kinirons & O'Mahony, 2004; Koukouritaki et al., 2004;
Stevens, 2006; Stevens et al., 2008), which fully develop only during
the ﬁrst year of life. In addition, there are some peculiarities in the
expression of speciﬁc isoforms, e.g. CYP3A7 is primarily a fetally
expressed form of the CYP3A subfamily. In the elderly population,
the ability to clear drugs is clearly decreased. This is particularly
relevant for drugs with narrow therapeutic window, including anti-
psychotics and antidepressants, anticoagulants, and betablockers.
Clearance of paracetamol and benzodiazepines is also lower in older
people. However, this does not seem to be a consequence of lower ex-
pression or activity of drug metabolizing enzyme systems. Studies in
human liver have found a modest increase in expression and activity
for most CYPs during life, particularly CYP2C9, which remained signif-
icant after correcting for multiple testing, while the inﬂuence of age
on CYPs 1A2, 2A6, 2B6, 2C8, and 3A4 partially interacted with sex
(Yang et al., 2010). Other reasons for limited drug clearance in the el-
derly are polypharmacy, i.e. inhibition of enzymes due to the concom-
itant intake of several potentially interacting drugs, as well as reduced
liver blood ﬂow and renal function (Cotreau et al., 2005).
Age-associated changes in expression of genes involved in xenobiotic
metabolism have also been identiﬁed in rats (Mori et al., 2007) and in
long-lived mutant mice (Amador-Noguez et al., 2007).
Disease states generally have a negative effect on drug metabo-
lism capacity. In liver cirrhosis changes in the architecture of the
liver resulting in reduction of blood ﬂow, loss of functional hepato-
cytes, and decreased drug metabolizing enzymes contribute to de-
creased drug metabolism capacity and lower synthesis of serum
proteins, leading on the one hand to decreased clearance but onEM
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Fig. 2. Sparteine oxidation phenotype and genotype distribution in a German population
2008). Reproduced by permission of The Royal Society of Chemistry.the other to increased unbound drug levels due to decreased plas-
ma protein binding (Elbekai et al., 2004; Edginton & Willmann,
2008).
During infection, inﬂammation and cancer, circulating proinﬂam-
matory cytokines such as interleukin (IL)-1β, TNF-α and IL-6, which
act as signalingmolecules to elicit marked changes in liver gene expres-
sion proﬁles, lead to severe downregulation of many drugmetabolizing
enzymes (Slaviero et al., 2003; Aitken et al., 2006). The mechanism of
these effects has been shown to be at least in part due to transcriptional
suppression (Jover et al., 2002; Aitken et al., 2006; Aitken & Morgan,
2007). Alcoholic and non-alcoholic fatty liver disease (NAFLD) are con-
ditions characterized by the abnormal retention of large amounts of tri-
glycerides which are accumulated in fat vesicles. NAFLD is associated
with diabetes, obesity andmetabolic syndrome and in severe cases pro-
ceeds to steatohepatitis (NASH). While the majority of studies on drug
metabolism in NAFLD were carried out in overweight rat or genetically
obese db/db mouse models, human studies are rare. Available data
show moderately reduced expression for most but not all CYP1-3 en-
zymes (Naik et al., 2013). Notably, CYP2E1 and fatty-acid metabolizing
CYP4A proteins are upregulated and likely contribute to in the genera-
tion of free radicals, lipid peroxidation, mitochondrial damage and he-
patic ﬁbrosis (Gómez-Lechón et al., 2009; Buechler & Weiss, 2011).
Overall the data suggest that drug metabolism is only moderately af-
fected by steatosis, whereas in NASH it may be more strongly affected,
comparable to other inﬂammatory conditions (Lake et al., 2011). The in-
ﬂuence of further disease states has been reviewed by others
(Villeneuve & Pichette, 2004; Kim & Novak, 2007).
3. Family CYP1: CYP1A1, CYP1A2, CYP1B1
3.1. Regulation and variability of gene expression
The CYP1 family comprises three functional genes in two subfam-
ilies. The highly conserved CYP1A1 and CYP1A2 genes consist of seven
exons and six introns and are located on chromosome 15q24.1, where-
as CYP1B1 consists of only three exons located on chromosome 2p22.2,
which however encode the largest human P450 in terms of mRNA sizeduplicated gene 
normal allele 
partially defective allele 
null allele 
PM 
Poor Metabolizer
rmediate 
tabolizer 
10010 MRS
(n=308). MRS: urinary metabolic ratio for sparteine (Raimundo et al., 2004; Zanger,
110 U.M. Zanger, M. Schwab / Pharmacology & Therapeutics 138 (2013) 103–141and number of amino acids (Murray et al., 2001; Nelson et al., 2004). In
humans CYP1A2 is constitutively expressed at higher levels only in
liver (Table 2). Estimations of the average abundance range from ~18
to 25 pmol per mg of microsomal protein determined by mass
spectrometry (Kawakami et al., 2011; Ohtsuki et al., 2012) up to
65 pmol/mg determined immunologically (Shimada et al., 1994;
Klein et al., 2010), representing ~4–16% of the total hepatic P450 pool
(Table 2). In contrast, CYP1A1 and CYP1B1, both of which are primarily
extrahepatically expressed enzymes (Ding & Kaminsky, 2003; Du et al.,
2006; Paine et al., 2006; Bièche et al., 2007; Dutheil et al., 2008;
Michaud et al., 2010), are found in liver at levels below 3 pmol/mg
(Stiborová et al., 2005) or at undetectable levels (Chang et al., 2003),
respectively.
The CYP1A1 and CYP1A2 genes are oriented head-to-head, sharing a
23 kb bi-directional promoter, which contains at least 13 Ah-receptor
(AhR) response elements, some which appear to regulate transcription
of both genes coordinately (Ueda et al., 2006; Jorge-Nebert et al., 2010).
Consequently, both genes are highly inducible by numerous xenobi-
otics which act as AhR ligands such as methylcholanthrene and
other polycyclic aromatic hydrocarbons, dioxins, β-naphthoﬂavone
(Table 3; Nebert et al., 2004), as well as atypical inducers including
omeprazole and primaquine which regulate transcription through the
same response elements, but without binding to the AhR (Yoshinari
et al., 2008). Typical exogenous sources of AhR activators are
natural combustion products, dietary constitutents (e.g. in broccoli),
and chemical manufacturing by-products (e.g. dioxins). Induction of
CYP1A2 by smoking is well established and has been conﬁrmed in
recent in vivo studies (Ghotbi et al., 2007; Dobrinas et al., 2011).
Numerous endogenous ligands such as eicosanoids have also been
proposed to regulate expression of CYP1 genes (Nebert & Karp, 2008).
Interestingly, both CYP1A1 and 1A2 are also inducible by phenobarbi-
tal, and transactivation of human CYP1A promoter constructs by the
human constitutive androstane receptor (CAR) was shown to be medi-
ated through a common ER8 cis-element (Yoshinari et al., 2010). In
contrast, PXR-dependent regulation of CYP1A2 appears to be negligible
as shown in vivo with the prototypical PXR ligand rifampin (Backman
et al., 2006) and in human hepatocytes, where CYP1A2 was refractory
to induction by statins (Feidt et al., 2010). Although CYP1B1 is princi-
pally regulated in similar ways, its promoter is distinct from that of
the two related CYP1A genes, but also contains AhR binding sites as
well as AhR-independent response elements, to which heterodimers
between ARNT and the hypoxia response factor Hif-1α can bind
(Schults et al., 2010).
A number of nongenetic factors inﬂuence CYP1A2 in vivo activity
and/or hepatic expression levels. Decreased expression was found in
liver donors with elevated liver function parameters, increased
C-reactive protein (a marker of inﬂammation), and cholestasis
(Klein et al., 2010). CYP1A2 activity in vivo was reported to be higher
in men than in women for several substrates including the conversion
of caffeine to paraxanthine (Relling et al., 1992; Ou-Yang et al., 2000).
However recent studies failed to conﬁrm such a difference in vivo
(Ghotbi et al., 2007; Dobrinas et al., 2011) and in human liver tissue
at the protein level (Klein et al., 2010) and at the mRNA level
(Zhang et al., 2011). A possible explanation for the discrepant results
may be that strong confounders of CYP1A2 activity, such as smoking
and oral contraceptives (inhibition, see below), have not been consis-
tently considered in all studies. The issue of a sex-bias in CYP1A2
expression and/or function thus remains controversial.
Evidence for epigenetic regulation of CYP1A2 expression was
shown by measuring the extent of DNA methylation of a CpG island
close to the translation start site, which was inversely correlated to
hepatic CYP1A2 mRNA levels (Ghotbi et al., 2007; Dobrinas et al.,
2011). Despite the common inducible regulation of CYP1A1 and
1A2, their ontogenic patterns differ substantially in that CYP1A1 is
expressed earlier in embryogenesis and both CYP1A1 and CYP1B1
are primarily found in extrahepatic tissues (Table 2). Notably,CYP1B1 is expressed in various cell types of the human and mouse
eye, where it plays a still undeﬁned role in the development of prima-
ry congenital glaucoma, an inheritable disease leading to blindness
(Vasiliou & Gonzalez, 2008). CYP1B1 has furthermore been found at
higher levels in tumorous compared to normal tissues and has been
proposed as an early stage tumor marker (Murray et al., 1997,
2001). CYP1B1-null mice were resistant to cancerogenic toxicity by
7,12-dimethylbenz[a]anthracene because they lacked metabolic
activation to the procarcinogenic 3,4-dihydrodiol metabolite in ﬁbro-
blasts, emphasizing the importance of extrahepatic CYP1B1 for carci-
nogenesis (Buters et al., 1999).
3.2. Role of CYP1 enzymes in drug metabolism
Catalytic activities of the CYP1 enzymes are overlapping and
include hydroxylations and other oxidative transformations of many
polycyclic aromatic hydrocarbons and other aromatic substances.
Whereas CYP1A1 prefers planar aromatic hydrocarbons, CYP1A2
shows a preference for aromatic amines and heterocyclic compounds
(Table 3). The crystal structure of CYP1A2 in complex with α-
naphthoﬂavone revealed a rather compact active site with a cavity
volume of 375 Ǻ3, which is larger than that of CYP2A6 (260 Ǻ3) but
much smaller compared to CYPs 3A4 and 2C8 (~1400 Ǻ3; Sansen et
al., 2007). Prototypical biotransformations catalyzed by CYP1A2 in-
clude 7-ethoxyresoruﬁn O-deethylation, phenacetin O-deethylation,
and caffeine N3-demethylation to paraxanthine, which are commonly
used for in vitro or in vivo phenotype determination (Fuhr et al.,
2007; Zhou et al., 2009). Due to its relatively high expression in
liver, CYP1A2 plays a signiﬁcant role in the metabolism of several
clinically important drugs (Gunes & Dahl, 2008; Zhou et al., 2009).
These include analgesics and antipyretics (acetaminophen, phenace-
tin, lidocaine), antipsychotics (olanzapine, clozapine), antidepres-
sants (duloxetine; Lobo et al., 2008), anti-inﬂammatory drugs
(nabumetone; Turpeinen et al., 2009), cardiovascular drugs
(propranolol, guanabenz, triamterene), the cholinesterase inhibitor
tacrine used for the treatment of Alzheimer's disease, the muscle re-
laxant tizanidine (Granfors et al., 2004), the hypnotic zolpidem used
in the short term treatment of insomnia, the drug riluzole used to
treat amyotrophic lateral sclerosis, the 5-lipoxygenase inhibitor
zileuton, among others (Table 3). Some drugs are bioactivated by
CYP1A2, including the antiandrogen ﬂutamide (Kang et al., 2008).
Endogenous substrates include arachidonic acid, prostaglandins,
oestrogens, melatonin and retinoic acid (Nebert & Dalton, 2006). In
addition, benzo[a]pyrene and diverse other procarcinogens such as
arylarenes, nitroarenes, and arylamines, present in charbroiled food
and industrial combustion products are bioactivated by CYP1 en-
zymes to reactive and carcinogenic intermediates able to cause DNA
damage. Drug treatment with CYP1A2 substrates is sensitive to
drug-interactions caused by reversible or irreversible inhibition of
the enzyme by several small molecule inhibitors that ﬁt the active
site, or by AhR-mediated gene induction (Table 3). Some of the
most potent inhibitors are α-naphtoﬂavone (Kib50 nM) and the se-
lective serotonin reuptake inhibitor (SSRI), ﬂuvoxamine (Ki~0.2 μM;
Hiemke & Härtter, 2000).
3.3. Genetic polymorphisms and functional impact
Common polymorphisms in the CYP1 family have been found to
be of limited impact on drug metabolism. Due to the role of all CYP1
enzymes in procarcinogen bioactivation many studies investigated
their association to various forms of cancer. Rare variants at the
CYP1B1 locus result in primary congenital glaucoma although no con-
sistent correlation has been observed between the severity of the
glaucoma phenotype and the molecular CYP1B1 genotype (Vasiliou
& Gonzalez, 2008).
Ta
bl
e
2
H
ep
at
ic
an
d
ex
tr
ah
ep
at
ic
ex
pr
es
si
on
pr
oﬁ
le
s
of
hu
m
an
cy
to
ch
ro
m
es
P4
50
an
d
PO
R.
CY
P
Li
ve
r
ab
un
da
nc
e
(p
m
ol
/m
g)
%
of
he
pa
ti
c
P4
50
po
ol
A
dr
en
al
Br
ai
n
(c
or
te
x)
H
ea
rt
K
id
ne
y
Lu
ng
O
va
ry
Pl
ac
en
ta
Pr
os
ta
te
Sk
in
/k
er
at
in
oc
yt
es
Sm
al
li
nt
es
ti
ne
Te
st
is
CY
P1
A
1
b
3a
b
1
R
b
RP
c
R
d
R
b
R
e,
b
N
.Q
.b
R
b
R
b
R
f
RP
g
R
b
CY
P1
A
2
17
.7
—
65
h
,i,
k
,l
4.
4–
16
.3
R
b
N
.D
.m
N
.D
.b
R
b
N
.D
.b
N
.D
.b
N
.D
.b
R
b
N
.D
.f
N
.D
.b
,p
R
b
CY
P1
B1
N
.D
.n
0
R
b
RP
c,
m
R
b
R
b
R
e,
b
R
b
R
b
R
b
R
f
R
b
,p
R
b
CY
P2
A
6
14
–
56
h
,o
,k
,l
3.
5–
14
R
b
N
.D
.c,
m
N
.D
.b
R
b
R
e
R
b
R
b
N
.D
.p
R
b
CY
P2
B6
6.
9–
21
q
,r
,s
,k
,l
1.
7–
5.
3
R
b
RP
t,
m
R
d
RP
A
u
,b
R
e,
b
R
b
RA
v
R
b
N
.D
.f
N
.D
.p
R
b
CY
P2
C8
29
.3
–
30
w
,k
,l
~7
.5
R
b
R
c,
m
RP
A
x
,d
R
b
R
e,
b
R
b
R
b
R
b
R
y,
b
,p
R
b
CY
P2
C9
18
–
11
6q
,z
,A
,k
,l
4.
5–
29
R
b
N
.Q
.m
R
x
,d
R
b
R
b
R
b
R
b
R
b
R
f
RP
A
y,
g,
b
,p
R
b
CY
P2
C1
9
3.
6–
15
z,
k
,l
0.
9–
3.
8
R
b
N
.D
.m
R
b
R
b
R
b
R
b
R
b
R
f
RP
A
y,
g,
b
,p
R
b
CY
P2
D
6
5–
17
h
,B
,C
,k
,l
1.
3–
4.
3
R
b
RP
D
,E
,m
R
b
R
e,
b
R
b
R
b
R
b
R
f
RP
g,
b
,p
R
b
CY
P2
E1
22
–
66
h
,k
,l
5.
5–
16
.5
R
b
RP
m
R
d
R
b
R
e,
b
R
b
R
b
R
f
R
b
,p
R
b
CY
P2
J2
1–
2F
b
1
R
b
RP
m
RP
x
,b
,d
R
b
R
e,
b
R
b
R
b
R
b
RP
g,
b
,p
R
b
CY
P3
A
4
58
–
14
6h
,G
,H
,k
,l,
M
14
.5
–
37
R
b
N
.D
.m
N
.D
.d
RP
A
u
,b
R
e,
b
N
.Q
.b
N
.D
.b
R
b
R
f
RP
A
b
,g
,p
R
b
CY
P3
A
5
3.
5–
4G
,k
,l
~1
R
b
R
m
N
.D
.d
RP
A
u
,b
,K
R
e,
b
R
b
R
b
R
b
RP
G
,b
,g
,p
R
b
PO
R
56
–
72
L,
l
0.
14
–
0.
18
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
U
bi
qu
it
ou
s
R,
RN
A
de
te
ct
ed
by
re
al
-t
im
e
PC
R
(N
.D
.,
no
td
et
ec
ta
bl
e;
ve
ry
lo
w
va
lu
es
re
po
rt
ed
as
N
.Q
.,
no
tq
ua
nt
iﬁ
ab
le
);
P,
pr
ot
ei
n
de
te
ct
ed
by
W
es
te
rn
bl
ot
,i
m
m
un
oh
is
to
ch
em
is
tr
y,
or
m
as
s
sp
ec
tr
om
et
ry
(a
ve
ra
ge
he
pa
ti
c
P4
50
po
ol
as
su
m
ed
as
0.
4
nm
ol
/m
g
m
ic
ro
so
m
al
pr
ot
ei
n)
;A
,e
nz
ym
e
ac
ti
vi
ty
de
te
ct
ed
us
in
g
ap
pr
op
ri
at
e
pr
ob
e
dr
ug
.D
at
a
co
m
pi
le
d
fr
om
a,
St
ib
or
ov
á
et
al
.,
20
05
;b
,B
iè
ch
e
et
al
.,
20
07
;c
,D
ut
he
il
et
al
.,
20
08
;d
,M
ic
ha
ud
et
al
.,
20
10
;e
,D
in
g
&
K
am
in
sk
y,
20
03
;f
,D
u
et
al
.,
20
06
;g
,P
ai
ne
et
al
.,
20
06
;
h,
Sh
im
ad
a
et
al
.,
19
94
;
i,
K
le
in
et
al
.,
20
10
;
k,
K
aw
ak
am
ie
t
al
.,
20
11
;
l,
O
ht
su
ki
et
al
.,
20
12
;
m
,D
ut
he
il
et
al
.,
20
09
;
n,
Ch
an
g
et
al
.,
20
03
;
o,
H
ab
er
le
t
al
.,
20
05
;
p,
Th
el
en
&
D
re
ss
m
an
,2
00
9;
q,
Co
lle
r
et
al
.,
20
02
;
r,
La
m
ba
et
al
.,
20
03
;
s,
H
of
m
an
n
et
al
.,
20
08
;
t,
M
ik
sy
s
et
al
.,
20
03
;
u,
A
le
ks
a
et
al
.,
20
05
;
v,
W
an
g
et
al
.,
20
10
a;
w
,N
ar
ah
ar
is
et
ti
et
al
.,
20
10
;
x,
D
eL
oz
ie
r
et
al
.,
20
07
;
y,
Lä
pp
le
et
al
.,
20
03
;
z,
K
ou
ko
ur
it
ak
ie
t
al
.,
20
04
;
A
,R
et
ti
e
&
Jo
ne
s,
20
05
;
B,
Za
ng
er
et
al
.,
20
01
;
C,
La
ng
en
fe
ld
et
al
.,
20
09
;
D
,S
ie
gl
e
et
al
.,
20
01
;
E,
M
ik
sy
s
et
al
.,
20
02
;
F,
Ya
m
az
ak
ie
t
al
.,
20
06
;
G
,L
in
et
al
.,
20
02
;
H
,W
ol
bo
ld
et
al
.,
20
03
;
K
,B
ol
br
in
ke
r
et
al
.,
20
12
;
L,
G
om
es
et
al
.,
20
09
;
M
,W
es
tl
in
d-
Jo
hn
ss
on
et
al
.,
20
03
.
111U.M. Zanger, M. Schwab / Pharmacology & Therapeutics 138 (2013) 103–1413.3.1. CYP1A1
Of four common variants originally termed m1 to m4, only the
nonsynonymous m2 variant (CYP1A1*2C, 2454A>G, Ile462Val) has
been clearly associated with 6- to 12-fold higher enzymatic activity
towards 17β-estradiol and estrone (Kisselev et al., 2005). This variant
has a global minor allele frequency (gMAF) of 12% but it is more com-
mon among Asians and Hispanics than in other populations (Table 1).
3.3.2. CYP1A2
Brøsen and colleagues investigated the heritability of caffeine meta-
bolic ratio as a CYP1A2 activity marker in a large cohort (n=378) of
mono- and dizygotic twins selected to exclude the inﬂuence of smoking,
oral contraceptives and sex and they found indication for a strong over-
all heritability of 0.72 (Rasmussen et al., 2002). The CYPallele website
(last accessed: December 2012) lists 21 deﬁned alleles and numerous
haplotype variants, some of which are associated with altered expres-
sion or inducibility, or code for proteins with altered enzyme activity.
The Arg431Trp substitution (CYP1A2*6), which is located in the “mean-
der” peptide, a region critical for maintenance of protein tertiary struc-
ture, was shown to result in nonfunctional protein (Zhou et al., 2004).
However due to their rare occurrence this and other amino acid variants
(Palma et al., 2010) are of limited clinical value. The 5′-upstream variant
3860G>A (CYP1A2*1C) was linked to decreased inducibility by smoking
based on promoter analyses and to decreased caffeine 3-demethylation
in Japanese smokers (Nakajima et al., 1999). The intron 1 polymorphism
–163C>A (CYP1A2*1F) located downstream of the untranslated ﬁrst
exon was associated with increased enzyme inducibility in German
(Sachse et al., 1999) and Swedish (Ghotbi et al., 2007) smokers and in
Swedish and Serbian heavy coffee consumers (Djordjevic et al., 2010).
The opposite effect of the two variants is consistent with the ﬁndings
that carriers of the combined genotype CYP1A2*1C/*1Fwere not induced
by omeprazole (Han et al., 2002). However there are also several contro-
versial studies and thus it is so far unclear whether the SNP rs762551
(Table 1) represents the causal variant or whether linkage to other var-
iants may be responsible for the different reported results across various
populations. It should also be noted that the C-allele is considered as the
reference allele, even though it is the rarer allele in most populations,
and that some authors use the opposite allele designation. Additional
CYP1A2 SNPs but so far no copy number variants were found in recent
studies where CYP1A2 has been resequenced in individuals from differ-
ent populations (Jiang et al., 2005; Browning et al., 2010).
Despite this multiplicity of CYP1A2 polymorphisms, attempts to
explain the suggested heritability in CYP1A2 phenotype by relating com-
mon SNPs to phenotype remained disappointing and it was suggested
that no single SNP or haplotype in the CYP1A2 gene has a clear predictive
value (Jiang et al., 2006). Klein and coworkers investigated the inﬂuence
of nongenetic factors and of 136 gene polymorphisms in the CYP1A locus
(15 SNPs) and in 16 other candidate genes from different pathways on
hepatic CYP1A2 mRNA and protein expression as well as phenacetin
O-deethylase activity phenotypes (Klein et al., 2010). Remarkably, 10
SNPs in the ARNT, AhRR, HNF1α, IL1β, SRC-1, and vitamin D receptor
(VDR) genes, but none of the CYP1A-locus showed consistent associa-
tions by univariate analysis. Multivariate linear modeling indicated that
genetic polymorphisms explained about 35% of hepatic CYP1A2 activity
variation,whereas slightly more than 40% of the variationwas explained
by nongenetic and genetic factors together. This study indicated that ad-
ditional genetic factors outside the CYP1A locusmay have a greater inﬂu-
ence on CYP1A2phenotype thanpolymorphismswithin theCYP1A locus.
3.3.3. CYP1B1
CYP1B1 was identiﬁed by genetic linkage analysis and mutation
studies as causative gene of primary congenital glaucoma, an inherit-
able neurodegenerative disease leading to blindness (Vasiliou &
Gonzalez, 2008). Over 80 mutations, mostly missense or nonsense
mutations, deletions, insertions and/or duplications, were identiﬁed
in patients with various forms of glaucoma. Some of them are
Table 3
Chemical interaction proﬁles of human hepatic drug metabolizing cytochromes P450.
CYP isoform, substrate structural characteristics Substrates/pathwaysa Inhibitorsb Inducersc
CYP1A2
Planar, aromatic, polyaromatic and heterocyclic
amides and amines
Acetanilide 4-hydroxylation (2E1) α-naphthoﬂavone Aminoglutethimide
Caffeine N3-demethylation Cimetidine Antipyrine
Chlorpromazine N-demethylation and 5-sulfoxidation (CYP3A4) Ciproﬂoxacin Bilirubin
Clozapine N-demethylation (3A4/5) Disulﬁram Carbamazepine
Estradiol 2-hydroxylation (3A4/5, 1A1) Enoxacin Coffee
7-ethoxyresoruﬁn O-deethylation (in vitro) Fluvoxamine Cruciferous vegetables (e.g. broccoli)
Flutamide 2-hydroxylation (3A4/5, 2C19) Furafylline Nelﬁnavir
Genistein 3′hydroxylation (2E1) Mexiletine Omeprazole
Guanabenz N-hydroxylation Moricizine Phenobarbital and other barbiturates
Lidocaine N-deethylation and 3′-hydroxylation (3A4, 2B6) Oral contraceptives Phenytoin
Melatonin 6-hydroxylation (1A1, 2C19) Tolfenamic acid Polycyclic aromatic hydrocarbons (PAHs,
charbroiled meat, cigarette smoke)Mianserin N-demethylation+N-oxidation (3A4/5)
Polychlorinated biphenylsNabumetone, 6-methoxy-2-naphthylacetic acid formation
PrimaquineNaproxen O-demethylation (2C9, 2C8)
RifampicineNNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone)
hydroxylation (most other CYPs) Ritonavir
Olanzapine N-demethylation+2-/7-hydroxylation (2D6)
Sulﬁnpyrazone
Perphenazine N-dealkylation (3A4/5, 2C9/19, 2D6) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
Phenacetin O-deethylation (1A1, 2A13)
Propafenone N-dealkylation (3A4/5)
Propranolol N-desisopropylation
Riluzole N-hydroxylation
Tacrine 1-hydroxylation
Theophylline 8-hydroxylation and N3-demethylation
Triamterene 4′-hydroxylation
CYP2A6
Nonplanar low MW molecules usually with 2 hydrogen
bond acceptors; includes ketones and nitrosamines
Bilirubin oxidation to biliverdin Decursinol angelate Artemisinin
Cotinine 3′-hydroxylation (R)-(+) menthofuran Carbamazepine
Coumarin 7-hydroxylation 8-methoxypsoralen Dexamethasone
1,7-dimethylaxanthine 8-hydroxylation Pilocarpine Estrogens
Efavirenz 7-hydroxylation (2B6) Selegiline Phenobarbital
Letrozole, carbinol formation (3A4/5) Tranylcypromine Rifampicin
Nicotine 5′-oxidation and N-demethylation (2B6)
Pilocarpine 3-hydroxylation
Tegafur, 5-ﬂuorouracil formation (1A2, 2C8)
CYP2B6
Neutral or weakly basic, mostly lipophilic non-planar
molecules with 1 to 2 hydrogen bond acceptors;
includes anaesthetics, insecticides and herbicides
Artemether O-demethylation (3A4/5) Bergamottin Artemisinine-type antimalarials
Artemisinin reductive cleavage (3A4/5) Clopidogrel Baicalin
Benzphetamine N-demethylation Clotrimazole Carbamazepine
7-Benzyloxyresoruﬁn O-debenzylation (3A4/5) Imidazoles Cyclophosphamide
Bupropion 4-hydroxylation Mifepristone (RU486) N,N-diethyl-m-toluamide (DEET)
Chlorpyrifos desulfuration (3A4/5, 1A2, 2C9/19) 2-phenyl-2-(1-piperdinyl)propane Efavirenz
Cyclophosphamide 4-hydroxylation (2C19, 3A4/5, 2C9, 2A6) Raloxifene 17-α-ethinylestradiol
N,N-diethyl-m-toluamide (DEET) ring methyl hydroxylation Sertraline Hyperforin
Efavirenz 8-hydroxylation (1A2, 3A4/5) thioTEPA Metamizole
Endosulfan S-oxidation (3A4) Ticlopidine Nelﬁnavir
7-ethoxy-4-triﬂuoromethylcoumarin (7-EFC) O-deethylation Voriconazole Nevirapine
Hexane 2-hydroxylation (2E1) Phenobarbital
Ifosfamide 4-hydroxylation (3A4/5) Phenytoin
Ketamine N-demethylation (3A4/5, 2C9) Rifampicin
S-mephenytoin N-demethylation (2C9) Ritonavir
S-mephobarbital N-demethylation Statins (e.g. atorvastatin)
Meperidine N-demethylation (3A4/5, 2C19) Vitamin D
Methadone N-demethylation (CYP2C, 3A4) St. John's Wort
Methamphetamine 4-hydroxylation and N-demethylation
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N-methyl-3,4-methylenedioxyamphetamine (MDMA, ecstasy)
N-demethylation (1A2)
Nevirapine 3-hydroxylation
Propofol hydroxylation (CYP2C9)
Selegiline N-demethylation and N-depropargylation (1A2)
Sertraline N-demethylation (2C19, 2C9, 3A4/5)
Temazepam N-demethylation
Testosterone 16α- and 16β-hydroxylation (3A4/5)
Tramadol N-demethylation (3A4/5)
CYP2C8
Relatively large and weakly acidic molecules;
includes antimalarials and oral antidiabetics
Amiodarone N-deethylation (3A4/5) Gemﬁbrozil Cyclophosphamide
Amodiaquine N-desethylation Montelukast Dexamethasone
Cerivastatin 6-hydroxylation and O-demethylation (3A4/5) Trimethoprim Fibrates (e.g. gemﬁbrozil)
Chloroquine N-deethylation (3A4/5) Hyperforin
Imatinib N-demethylationn (3A4/5) Imatinib
Montelukast 36-hydroxylation (3A4/5, 2C9) Lithocholic acid
Nicardipine debenzylation (3A4/5) Nelﬁnavir
Paclitaxel 6α-hydroxylation Paclitaxel
Pioglitazone hydroxylation (1A2, 2D6) Phenobarbital
Retinoic acid 4-hydroxylation (3A7, 3A4, 2C9) Phenytoin
Rosiglitazone N-demethylation and p-hydroxylation (2C9) Rifampicin
Troglitazone oxidation (3A4/5) Ritonavir
Statins (e.g. atorvastatin)
CYP2C9
Weakly acidic molecules with a hydrogen bond
acceptor; includes most NSAIDs
Acenocoumarol 6- and 7-hydroxylation (1A2, 2C19) Amiodarone Aprepitant
Candesartan O-deethylation Fluconazole Avasimibe
Chlorpropamide 2-hydroxylation (2C19) Naringenin Barbiturates
Celecoxib methylhydroxylation (3A4/5) Sulphaphenazole Bosentan
Dapsone N-hydroxylation (2C8) Tienylic acid Carbamazepine
Diclofenac 4′-hydroxylation Voriconazole Cyclophosphamide
Etodolac 6- and 7-hydroxylation Dexamethasone
Fluoxetine N-demethylation (2D6, 2C19, 3A4/5) Glutethimide
Flurbiprofen 4′-hydroxylation Hyperforin
Glibenclamide hydroxylation Nelﬁnavir
Glimepiride hydroxylation Nifedipine
Ibuprofen 2- and 3-hydroxylation (2C8, 3A4/5) Norethindrone
Indomethacine O-demethylation (2C8) Phenobarbital
Irbesartan hydroxylation Prednisone
Ketobemidone N-demethylation (3A4/5) Rifampicin
Lornoxicam 5′-hydroxylation Ritonavir
Losartan 2-step oxidation of –CH2OH (3A4/5) Statins (e.g. atorvastatin)
Meloxicam 5′-methylhydroxylation (3A4/5) St. John's Wort
Phenobarbital p-hydroxylation (2C19)
Phenytoin 4-hydroxylation (2C19)
Piroxicam 5′-hydroxylation
Rosuvastatin N-demethylation
Sulfamethoxazole N-hydroxylation
S-warfarin 7-hydroxylation (4F2)
Tetrahydrocannabinol 11-hydroxylation (3A4/5)
Tienilic acid S-oxidation
Tolbutamide 4′-hydroxylation (2C19)
Valproic acid 4-hydroxylation (2B6, 2A6)
Valsartan 4-hydroxylation
Zaltoprofen sulfoxidation
CYP2C19
Neutral or weakly basic molecules or amides with
2 or 3 hydrogen bond acceptors; includes most
proton pump inhibitors
Amitriptyline N-demethylation (2C8, 2C9) (−)-N-3-benzyl-phenobarbital Acetylsalicylic acid
Clomipramine 8-hydroxylation (1A2) Clopidogrel Antipyrine
Clopidogrel, 2-oxo-clopidogrel formation (3A4/5, 2B6, 1A2) Fluoxetine Artemisinin-type antimalarials
Hexobarbital 3′-hydroxylation Fluvoxamine Baicalin
(continued on next page)
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Table 3 (continued)
CYP isoform, substrate structural characteristics Substrates/pathwaysa Inhibitorsb Inducersc
Imipramine N-demethylation Naringenin Barbiturates
Lansoprazole 5-hydroxylation (3A4/5) (+)-N-3-benzyl-nirvanol Carbamazepine
Melatonin O-demethylation (1A2) Omeprazole Dexamethasone
Nelﬁnavir tert-butylamide-hydroxylation (M8) Ticlopidine Efavirenz
Omeprazole 5-hydroxylation (3A4/5) Voriconazole Hyperforin
Pantoprazole sulfoxidation (3A4/5) Nelﬁnavir
Progesterone 21-hydroxylation (2C9, 3A4/5) Rifampicin
Proguanil isopropyl oxidation and cyclization to cycloguanil (3A4/5) Ritonavir
R-mephobarbital 4-hydroxylation (2B6) St. John's Wort
Ranitidine N-demethylation (1A2, 2D6)
S-mephenytoin 4′-hydroxylation
Venlafaxin N-demethylation (2C9, 3A4/5)
Voriconazole N-oxidation (3A4/5)
CYP2D6
Basic molecules with protonatable nitrogen atom
4–7 Å from the metabolism site; includes many
plant alkaloids and antidepressants
Amitriptyline 10-hydroxylation (3A4/5) Bupropion No signiﬁcant induction by prototypical
P450 inducersAmphetamine 4-hydroxylation Celecoxib
Aprindine 5-hydroxylation Flecainide
Aripiprazole dehydrogenation (3A4/5) Fluoxetine
Atomoxetine 4-hydroxylation and N-demethylation Haloperidol
Bufuralol 1′-hydroxylation (1A2, 2C19) Methadone
Carvedilol 4′- and 5′-hydroxylation Paroxetine
Chlorpromazine 7-hydroxylation (1A2) Quinidine
Clomiphene 4-hydroxylation (2B6)
Codeine O-demethylation
Debrisoquine 4-hydroxylation
Desipramine 2-hydroxylation (2C19, 1A2)
Dextromethorphan O-demethylation (2C9/19)
Dihydrocodeine O-demethylation
Diphenhydramine N-demethylation (1A2, 2C9, 2C19)
Dolasetron 6-hydroxylation (3A4/5)
Donepezil O-demethylation (3A4/5)
Duloxetine 4-, 5-, 6-hydroxylations (1A2)
Flecainide meta-O-dealkylation (1A2)
Galantamine N-demethylation
Hydrocodone O-demethylation (3A4/5)
Imipramine 2-hydroxylation (2C19, 1A2)
Loratadine oxidation to desloratadine (3A4/5)
Metoclopramide N-deethylation (3A4/5)
Metoprolol α-hydroxylation and O-demethylation
Mexiletine p-, m-, and 2-methylhydroxylation (1A2)
Mianserin 8-hydroxylation (2B6, 3A4/5)
Minaprine 4-hydroxylation
Mirtazapine 8-hydroxylation (1A2, 3A4/5)
N-methyl-3,4-methylenedioxyamphetamine (MDMA, ecstasy) demethylenation (1A2)
Nortriptyline 10-hydroxylation (3A4/5)
Ondansetron 7- and 8-hydroxylation (3A4/5)
Oxycodone O-demethylation
Paroxetine demethylenation
Perhexiline hydroxylation
Procainamide N-hydroxylation
Promethazine hydroxylation
Propafenone 5-hydroxylation
Propranolol 4- and 5-hydroxylation (Masubuchi 1994)
Risperidone 9-hydroxylation (3A4/5)
Sparteine C-oxidation
Tamoxifen 4-hydroxylation (2C9)
Thioridazine sulfoxidation (3A4/5)
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Timolol hydroxylation (2C19)
Tramadol O-demethylation
Tropisetrone 5- and 6-hydroxylation (3A4/5)
Venlafaxin O-demethylation (2C19, 2C9)
Zuclopenthixol N-dealkylation (3A4/5)
CYP2E1
Small, generally neutral and hydrophilic, planar molecules;
includes aliphatic alcohols and halogenated alkanes
Aniline 4-hydroxylation Clomethiazole Acetone
Arachidonic acid ω-1-hydroxylation (1A1, 2D6) Diethyldithiocarbamate Ethanol
Benzene hydroxylation and hydrochinone formation Disulﬁram Isoniazid
Butadiene 1,2-epoxidation (2A6) 4-methylpyrazole Pyrazole
Chlorzoxazone 6-hydroxylation (1A2) Orphenadrine Various other solvents and chemicals
N,N-dimethylnitrosamine N-demethylation (2A6)
Enﬂurane oxidation and dehalogenation
Ethanol oxidation (major: ADH1)
Halothane hydroxylation (2A6, 3A4/5)
Isoﬂurane dehalogenation
Lauric acid (omega-1)-hydroxylation (4A11)
Para-nitrophenol 2-hydroxylation
Salicylic acid 5-hydroxylation (3A4/5)
Sevoﬂurane hydroxylation
Styrene 7,8-epoxidation
Tetrachloromethane dehalogenation (3A4/5)
Toluene benzylic hydroxylation (2B6, 2C8, 1A2)
Vinylchloride epoxidation
CYP2J2
Active site can accommodate large substrates similar
to CYP3A4 but more restrictive catalytic function
Albendazole S-oxidation Arachidonic acid None known
Amiodarone 4-hydoxylation α-naphthoﬂavone
Arachidonic acid epoxidation (mainly in heart; other CYPs) Danazol
Astemizole O-demethylation Hydroxyebastine
Cyclosporine A hydroxylation (major: 3A4/5) Ketoconazole
Ebastine t-butyl hydroxylation (3A4/5) Terfenadone
Danazol hydroxylation Tranylcypromine
Mesoridazine sulfoxidation (major: CYP3A4) Troglitazone
Terfenadine hydroxylation
CYP3A4/5
Large and lipophilic molecules of very diverse structures;
includes over 50% of all clinically used drugs
L-α-acetylmethadol (LAAM) N-demethylation (2B6) Azamulin Amprenavir
Aﬂatoxin B1 3α-hydroxylation and 8,9-epoxidation (1A2) Claritromycin Aprepitant
Alfentanil N-dealkylation Diltiazem Artemisinine-type antimalarials
Alprazolam α-hydroxylation Erythromycin Avasimibe
Antipyrine 4-hydroxylation (1A2) Ethinylestradiol Baicalin
Aprepitant N- and O-dealkylation (1A2, 2C19) Grapefruit juice Baribiturates
Atorvastatin o- and p-hydroxylation Isoniazid Bosentan
Budesonide 6β-hydroxylation Irinotecan Carbamazepine
Buprenorphine N-demethylation (2C8) Ketoconazole Dexamethasone
Buspirone 6′-hydroxylation Mibefradil Efavirenz
Carbamazepine 10,11-epoxidation (2C8) Mifepristone (RU486) Etravirine
Cholesterol 4β-hydroxylation Naringenin Ginkgo biloba
Cisapride N-dealkylation (2A6) Nicardipine Glucocorticoids
Citalopram N-demethylation (2C19, 2D6) Ritonavir Hyperforin
Clarithromycin 14-(R)-hydroxylation and N-demethylation Troleandomycin Imatinib
Clindamycin S-oxidation Verapamil Miconazole
Codeine N-demethylation (2B6) Voriconazole Mitotane
Cortisol 6β-hydroxylation Moricizine
Cyclobenzaprine (1A2, 2D6) Nafcillin
Cyclophosphamide N-dechloroethylation Nevirapine
Cyclosporine A hydroxylation (M1 and M17 formation) Oxcarbazepine
Dasatinib N-dealkylation Phenobarbital
Dexamethasone 6-hydroxylation Phenylbutazone
Dextromethorphan N-demethylation (2B6, 2C9/19)) Phenytoin
(continued on next page)
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Table 3 (continued)
CYP isoform, substrate structural characteristics Substrates/pathwaysa Inhibitorsb Inducersc
Dextropropoxyphene N-demethylation Rifabutin
Diazepam 3-hydroxylation and N-demethylation (2C19) Rifampicin
Dihydrocodeine N-demethylation Rifapentin
Diltiazem N-demethylation (2C8, 2C9) Ritonavir
Docetaxel hydroxylation Statins
Dolasetron N-oxidation St. John's Wort
Donezepil O-dealkylation (2D6) Sulﬁnpyrazone
Ebastine N-dealkylation Topiramate
Erlotinib O-demethylation (1A1/2) Troglitazone
Erythromycin N-demethylation (2B6) Valproic acid
Eszopiclone oxidation and N-demethylation (2E1) Vinblastine
17α-ethinyl estradiol 2-hydroxylation
Etoposide catechol metabolite formation
Felodipine oxidation to pyridine
Fenoﬁbrate deesteriﬁcation
Fentanyl N-dealkylation
Fluticasone 17β-carboxylic acid formation
Geﬁtinib O-demethylation (1A1/2D6)
Glyburide hydroxylation (2C9)
Granisetron N-demethylation
Haloperidol N-dealkylation (2D6)
Hydromorphone N-demethylation (2C9)
Ifosfamide N-dechloroethylation (2B6)
Ilaprazole sulfone formation
Irinotecan (CPT-11) oxidation to APC
Isotretinoin (13-cis- retinoic acid) 4-hydroxylation (2C8)
Lithocholic acid 6α-hydroxylation
Lopermide N-demethylation (2B6)
Midazolam 1′-hydroxylation
Mifepristone (RU-486) N-demethylation
Mirtazapine N-demethylation and N-oxidation
Morphine N-demethylation (2C8)
Nevirapine 2-hydroxylation
Nifedipine oxidation to pyridine
Oxycodone N-demethylation
Paracetamol oxidation to NAPQI (2E1, 2A6, 1A2, 2D6, 2C9/19)
Quetiapine N-dealkylation
Quinine 3-hydroxylation
Quinidine 3-hydroxylation and N-oxidation
Sildenaﬁl N-demethylation (2C9)
Simvastatin 6′-β-hydroxylation (2C8)
Sirolimus 16-O- and 39-O-demethylation and various hydroxylations
Tacrolimus O-demethylation
Teniposide O-demethylation
Testosterone 6β-hydroxylation (2C9, 1A1)
Tetrahydrocannabinol 7- and 8-hydroxylation
Tilidine N-demethylation
Tramadol N-demethylation (2B6)
Trazodone N-dealkylation to mCPP
Triazolam α- and 4-hydroxylation
Verapamil Nndemethylation to norverapamil (2C8)
Vincristine M1-formation (3A5>3A4)
Ziprasidone sulfoxidation (2C19)
Zolpidem hydroxylation (1A2)
Data were compiled from Anzenbacher & Zanger, 2012, and from the references cited in the text.
a Substrates/pathways are grouped by the major metabolizing P450 enzyme in liver with other contributing enzymes given in parentheses. Drugs selectively metabolized by one form and used for phenotyping are printed in bold-type.
Endogenous substrates are underlined.
b Inhibitors listed have shown to inhibit the respective P450 signiﬁcantly in vivo or in human liver microsomes; isoenzyme-selective inhibitors are shown in bold-type.
c Inducers that have been shown to induce the respective P450 signiﬁcantly in vivo or in human hepatocytes; isoenzyme-selective inducers are shown in bold-type.
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to lead to severely compromised enzyme function (Jansson et al.,
2001; Chavarria-Soley et al., 2008; Choudhary et al., 2008; Vasiliou
& Gonzalez, 2008). Because these mutations are rare in the general
population, their value as tumor markers or markers of altered
metabolism of drugs appears to be of limited value. More common
polymorphisms include ﬁve amino acid variants in different combina-
tions. Functional analysis of variant proteins coexpressed with P450
reductase in E. coli showed threefold increased Km towards 17β-
estradiol for the Leu432Val (CYP1B1*3) variant but little inﬂuence of
the Arg48Gly, Ala119Ser and Asn453Ser variants (Li et al., 2000).
This ﬁnding was however not reproduced in a yeast expression
study using the same substrate, whereas decreased Vmax and
increased Km towards 17β-estradiol was observed in combination
alleles CYP1B1*6 and CYP1B1*7 (Aklillu et al., 2002). The CYP1B1.7
variant was also found to have lower benzo[a]pyrene hydroxylase
activity. The Leu432Val variant was correlated to changed urinary
estrogen metabolites, indicating in vivo contribution of CYP1B1 to
estrogen catabolism (Napoli et al., 2009). These studies suggest that
the common amino acid variations have moderate to low substrate-
dependent effects on the catalytic properties of the enzyme.
3.4. Clinical impact of genetic variation
Because of the role of CYP1A and CYP1B enzymes in the metabo-
lism of procarcinogens and cellular signalling molecules, their poly-
morphisms have been extensively studied as susceptibility factors in
the context of various cancers (examples shown in Table 1). As this
topic is not systematically covered here, the reader is referred to re-
views and meta-analyses by others (Shi et al., 2008; Kaur-Knudsen
et al., 2009b; Sergentanis & Economopoulos, 2009; Shaik et al.,
2009; Economopoulos & Sergentanis, 2010; Yao et al., 2010a; Cui et
al., 2012; Li et al., 2012a; Wang et al., 2012).
DNA damage caused by CYP1A-activated tobacco smoke mutagens
may contribute to the development of coronary heart disease.
Cornelis and colleagues investigated this hypothesis by genotyping
873 Costa Rican subjects with myocardial infarction (MI) for CYP1A1
and CYP1A2 genotypes (Cornelis et al., 2004). While CYP1A1 genotype
had no inﬂuence, individuals homozygous for the low inducibility –
163C allele had increased risk, but surprisingly this was independent
of smoking status. The authors reasoned that activation of tobacco
smoke mutagens by CYP1A2 may not play a signiﬁcant role in CHD
but that an unknown compound, e.g. a coffee ingredient detoxiﬁed
by CYP1A2, may contribute to MI. This ﬁnding was however not
reproduced in a Tunisian population (Achour et al., 2011). The
controversial association between coffee intake and risk of MI was in-
vestigated with respect to the CYP1A2 –163C/A polymorphism by the
same researchers (Cornelis et al., 2006). Intake of coffee was associat-
ed with an increased risk of MI only among individuals with the
low-inducibility (−163C) allele in a dose-dependent way. This effect
was independent of smoking status and the authors suggested that an
unknown CYP1A2 substrate that is detoxiﬁed rather than activated
may play a role in CHD.
As CYP1A2 is the rate-limiting enzyme for metabolism of caffeine,
the most widely consumed psychoactive substance worldwide,
CYP1A2 polymorphism could play a role in habitual caffeine intake,
which is also regarded as a model for addictive behavior. Indeed,
twin studies suggest heritability estimates for heavy caffeine use of
up to 77% (Dvorak et al., 2003). Several genome-wide association
studies (GWAS) and GWAS meta-analyses involving many thousands
of subjects identiﬁed SNPs in the regulatory region of the CYP1A locus
(rs2472304, rs2472297) as well as SNPs in the AhR gene regulatory
region (rs4410790, rs6968865) along with genes related to addictive
behavior to be associated with habitual coffee intake (Dvorak et al.,
2003; Cornelis et al., 2011; Sulem et al., 2011). It would be highly in-
teresting to identify the causal variants for these associations. TheCYP1A2 low-inducibility –163C allele may also modify the risk of hy-
pertension in coffee drinkers, as suggested by one study (Palatini et
al., 2009).
These data collectively support a role of CYP1A2 polymorphism in
the metabolism and disposition of caffeine. Data concerning clinical
drug use are generally less convincing although some studies
reported a signiﬁcant inﬂuence. CYP1A2*1F/*1F genotype was associ-
ated with a 22% reduction of olanzapine serum concentration,
which was independent of any inducing agents, indicating a moder-
ately increased activity of the *1F allele per se (Laika et al., 2010). In
this study higher olanzapine concentrations were correlated to better
improvement of paranoid and depressive symptoms in patients with
schizophrenic disorders. In contrast, although CYP1A2 is the major
P450 enzyme for the metabolism of the antipsychotic, clozapine, clin-
ical studies did not conﬁrm an inﬂuence of CYP1A2 genotype (Van der
Weide et al., 2003; Jaquenoud Sirot et al., 2009). This was quite
surprising since smoking behavior strongly inﬂuenced clozapine
clearance and daily dose requirement.
In conclusion, the currently known polymorphisms in the CYP1A2
gene explain only a small fraction of the CYP1A2 variability in expres-
sion and function. GWAS and candidate gene studies indicate that
genetic determinants in other genes contribute to CYP1A2 activity.
4. Family CYP2
The CYP2 family contains 16 full-length genes, which all have 9
exons and 8 introns. Several of the most important hepatic drug me-
tabolizing CYPs but also extrahepatic enzymes and several “orphan”
P450s (Guengerich & Cheng, 2011) with still unclear function are
found in this family. The genes are spread over different chromo-
somes and organized in multi-gene clusters containing one or several
subfamilies (Hoffman et al., 2001; Nelson et al., 2004). The three
largest gene clusters are the CYP2ABFGST cluster on chromosome
19q13.2, which contains the CYP2A6 and CYP2B6 genes, the CYP2C
cluster on chromosome 10q23.33 with the CYP2C8, CYP2C9, and
CYP2C19 genes, and the CYP2D cluster on chromosome 22q13.1-2
with the only functional gene CYP2D6. In the evolution of rodents,
many of the CYP2 subfamilies expanded tremendously, making the
identiﬁcation of true orthologues between mouse and human P450s
especially challenging (Nelson et al., 2004). Most pharmacologically
important CYP2 genes are highly polymorphic, in particular CYP2A6,
CYP2B6, CYP2C9, CYP2C19, and CYP2D6. In this chapter, we focus on
the description of those genes and enzymes that are of highest impor-
tance for xenobiotic metabolism.
4.1. Subfamily CYP2A: CYP2A6, CYP2A7, CYP2A13
4.1.1. Regulation and variability of gene expression
The three full-length human CYP2A genes 2A6, 2A7, and 2A13 and
a split pseudogene CYP2A18P are found on a 370 kb gene cluster on
chromosome 19q13.2 that contains genes and pseudogenes of the
CYP2A, 2B, 2F, 2G, 2S and 2T subfamilies (Hoffman et al., 2001;
Nelson et al., 2004 Only CYP2A6 and CYP2A13 are functional whereas
CYP2A7 apparently encodes a nonfunctional gene, although CYP2A7
cDNA generates an immunoreactive protein unable to incorporate
heme (Ding et al., 1995; Hoffman et al., 2001). Human CYP2A6 is
mainly expressed in liver (Table 2), where mean expression levels
corresponding to ~4% of the hepatic P450 pool were found by Western
blot analysis (Shimada et al., 1994; Haberl et al., 2005)whilemass spec-
trometric studies foundmuch higher levels of ~50 pmol/mg (Ohtsuki et
al., 2012). Signiﬁcantly increased protein and mRNA levels were ob-
served in female liver donors (Al Koudsi et al., 2010) and decreased
levels of protein and activity in Japanese compared to Caucasian liver
donors (Shimada et al., 1996).
Transcriptional regulation of CYP2A6 involves several response
pathways. In human hepatocytes, the PXR and CAR activators
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ements (Itoh et al., 2006). Furthermore glucocorticoid receptor-
mediated activation of CYP2A6 transcription by dexamethasone was
reported to depend on HNF4α (Onica et al., 2008). In vivo,
estrogen-containing oral contraceptives can increase CYP2A6 activity
as measured by nicotine and cotinine clearance (Benowitz et al.,
2006). In vitro data indicate transcriptional upregulation of CYP2A6
via an estrogen receptor-dependent pathway (Higashi et al., 2007).
CYP2A13 codes for a catalytically active protein expressed at low
levels predominantly in the respiratory tract including the lung,
where expression levels decrease from nasal mucosa to peripheral
lung tissues (Leclerc et al., 2010; Raunio & Rahnasto-Rilla, 2012).
4.1.2. Role of CYP2A enzymes in drug metabolism
Human CYP2A6 has been recognized as the major isoform
involved in the oxidative metabolism of the psychoactive tobacco in-
gredient nicotine to the inactive cotinine (Raunio & Rahnasto-Rilla,
2012). Further metabolism of cotinine to 3′-hydroxycotinine is also
exclusively catalyzed by CYP2A6 in humans and in agreement with
higher expression of hepatic CYP2A6 in females, metabolism of nico-
tine to cotinine, and the trans-3′-hydroxycotinine/cotinine ratio were
signiﬁcantly higher in women than in men (Benowitz et al., 2006).
The 7-hydroxylation of coumarin is a selective marker activity for
CYP2A6 (Pelkonen et al., 2000; Fuhr et al., 2007). Major racial differ-
ences exist, e.g. only 1% of white subjects but to up to 20% of Asians
were characterized as poor metabolizers (Shimada et al., 1996;
Raunio et al., 2001). CYP2A6 was identiﬁed as the main isoenzyme re-
sponsible for bioactivation of the cancer prodrug tegafur to 5-FU
(Komatsu et al., 2000), efavirenz 7-hydroxylation, a minor pathway
compared to the major 8-hydroxylation catalyzed by CYP2B6 (Desta
et al., 2007), and the biotransformation of the aromatase inhibitor,
letrozole, to its major, pharmacologically inactive carbinol metabolite,
4,4′-methanol-bisbenzonitrile (Murai et al., 2009). Furthermore,
CYP2A6 contributes to the metabolism of a number of clinically
used drugs such as disulﬁram, fadrozole, halothane, osigamone, me-
thoxyﬂurane, pilocarpine, promazine, and valproic acid (Di et al.,
2009). An endogenous substrate of CYP2A6 that was only recently
identiﬁed is bilirubin (Abu-Bakar et al., 2012). CYP2A13 has similar
substrate speciﬁcity and also metabolizes coumarin and nicotine,
but has been shown to be the most efﬁcient metabolic activator of
NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), a major
tobacco procarcinogen (Su et al., 2000).
4.1.3. Genetic polymorphisms and functional impact
Both increased and decreased gene expression and enzyme activ-
ity have been associated with genetic variation in the CYP2A6 gene. At
present, 38 distinct star-alleles with deleted or duplicated genes, gene
conversions, nucleotide deletions and insertions, as well as coding
and non-coding SNPs are described on the CYPalleles website. Some
of these variants were shown to change mRNA and/or protein expres-
sion levels or to affect the structure and function of the protein
(Table 1). The prevalence of low-activity or loss-of-function CYP2A6
alleles was estimated to be ~9% in Caucasians, ~22% in Africans and
up to 50% in Asians (Nakajima et al., 2006; di Iulio et al., 2009). A de-
tailed compilation of the known structural changes and their func-
tional impact was presented by Mwenifumbo and Tyndale (2009).
Loss-of-function alleles include the CYP2A6*2[Leu160His] and the
*4A-H deletion alleles, that have been shown to dramatically reduce
enzyme activity in vivo in homozygous or hemizygous combination,
resulting in the poor metabolizer phenotype in affected individuals
(Table 1). The most frequent null alleles in Asians are the *4A to *4H
hybrid-deleted alleles which consist of a CYP2A7-derived 5′ part and
a 3′ part of CYP2A6 origin. The decreased gene copy number associat-
ed with these gene deletions appears to be correlated to decreased
expression and activity (Haberl et al., 2005; Mwenifumbo et al.,2010). The *4A deletion variant is rare in Caucasians and Africans
but present at up to ~20% frequency in Asian populations (Table 1).
CYP2A6*2[Leu160His] encodes an unstable protein that fails to
incorporate heme. Its frequency is ~1–5% in Caucasians and lower in
Africans and Asians. In a study involving 156 liver samples from
Caucasians, resequencing revealed 33 haplotypes of which two (*9B,
containing a -48T>G TATA-box polymorphism, and the 2A7/2A6 re-
combination allele *12B) were major genetic determinants associated
with decreased hepatic expression (Haberl et al., 2005). Additional al-
leles with functional impact include CYP2A6*7, *10, *17, and *35 asso-
ciated with reduced enzyme activity in homozygous or hemizygous
individuals. The *7[Ile471Thr] and *10 [Ile471Thr; Arg485Leu] alleles
are Asian-speciﬁc and *17 [Val365Met] was only found in African
Americans. The CYP2A6*5, *6, *11, *19, and *20 alleles were shown
to result in reduced activity by heterologous expression. Further var-
iants shown to affect expression or function include several promoter
variants that result in decreased expression (Von Richter et al.,
2004b). Apart from the low copy number variants with deleted
CYP2A6, increased copy number variants termed *1X2A and *1X2B
appear to be correlated to increased activity (Fukami et al., 2007).
4.1.4. Clinical impact of genetic variation
Most pharmacogenetic studies involving CYP2A6 were carried out
to study the effect of genotype either on nicotine metabolism,
smoking behavior, nicotine withdrawal symptoms or lung cancer
risk (Benowitz et al., 2006; Nakajima et al., 2006; Mwenifumbo &
Tyndale, 2007; Rossini et al., 2008). For example, compared to sub-
jects with reference genotype (*1/*1), heterozygotes of alleles *9
and *12 had on average 80% of normal activity, whereas *4 heterozy-
gotes or carriers of two low-activity alleles had ~50% nicotine
C-oxidation activity (Benowitz et al., 2003). Because of its major con-
tribution to nicotine metabolism, the enzyme has been proposed as a
novel target for smoking cessation. In a nicotine-replacement clinical
trial, the group with low-activity alleles had 50% reduced CYP2A6 ac-
tivity before treatment and reached 44% higher steady-state plasma
levels of nicotine (Malaiyandi et al., 2006). Moreover, severe nicotine
withdrawal symptoms related to nicotine dependence during
smoking cessation were higher in CYP2A6-genotyped Japanese
high-activity subjects (50.0%) compared to the low-activity group
(22.2%; (Kubota et al., 2006). Recent studies investigated CYP2A6
and the CHRNA5-CHRNA3-CHRNB4 nicotinic acetylcholine receptor
gene polymorphisms in relation to smoking behavior and lung cancer
risk. In ever-smokers of European ancestry (417 lung cancer patients)
versus control subjects, increased cigarette consumption, nicotine de-
pendence, and lung cancer risk were independently and additively
associated with genetic variation in CYP2A6 and the acetylcholine re-
ceptor gene cluster. The combined risk group exhibited the greatest
lung cancer risk with an odds ratio of ~2 (Wassenaar et al., 2011).
CYP2A6 variants were also associated to smoking behavour (ciga-
rettes smoked per day) at genome-wide signiﬁcance (Thorgeirsson
et al., 2010).
The signiﬁcance of CYP2A6 polymorphism for drug therapy is em-
phasized by the following two examples. CYP2A6 is a major enzyme
for the bioactivation of the cancer prodrug tegafur to 5-FU (Komatsu
et al., 2000). A prospective pharmacokinetic study in Japanese patients
with advanced cancers revealed that CYP2A6 variants determined oral
clearance of tegafur as shown by multivariate regression analysis and
that tegafur clearancewas lowest in homozygous or compound hetero-
zygous CYP2A6 variant allele carriers (Fujita et al., 2008). Another ex-
ample is efavirenz, an antiretroviral drug with the major metabolic
pathway catalyzed by CYP2B6, which leads to 8-hydroxy efavirenz.
As initially shown in human liver microsomes, the minor 7-hydroxy-
efavirenz metabolite is mainly formed by CYP2A6 (Desta et al., 2007).
While the wide interindividual variability in efavirenz plasma exposure
is largely explained by CYP2B6 polymorphisms, the CYP2A6-dependent
accessory pathway becomes critically limiting for drug clearance in
119U.M. Zanger, M. Schwab / Pharmacology & Therapeutics 138 (2013) 103–141patients with genetically impaired CYP2B6 (Di Iulio et al., 2009). As
combined CYP2B6 and CYP2A6 genetic deﬁciency occurs at signiﬁcant
frequency in various human populations, the CYP2A6 polymorphism
may be a clinically relevant determinant of extremely high efavirenz
exposure in HIV patients. A more recent pharmacogenetic study
found that CYP2A6 genotype is also a predictor for plasma letrozole
concentrations in postmenopausal women with breast cancer (Desta
et al., 2011).
4.2. Subfamily CYP2B: CYP2B6
4.2.1. Regulation and variability of gene expression
The functional CYP2B6 gene and the nonfunctional pseudogene
CYP2B7P are located in a tandem head-to-tail arrangement within the
large CYP2ABFGST gene cluster on chromosome 19 (Nelson et al.,
2004). Although the genomic structures of the human and rodent
CYP2B genes are very different with more functional genes expressed
in the animals, strong inducibility by phenobarbital is a hallmark of
CYP2B genes, and similar mechanisms apply in humans and animals.
The major discovery in this ﬁeld was the identiﬁcation of the orphan
nuclear receptor CAR (NR1I3) as the major regulator of CYP2B6 by
drugs and other xenobiotics via a phenobarbital-responsive enhancer
module (PBREM) at –1.7 kb of the CYP2B6 promoter (Sueyoshi et al.,
1999). Later it was found that PXR (NR1I2) also contributes to
CYP2B6 induction via a distal xenobiotics-responsive enhancer module
(XREM, −8.5 kb; (Wang et al., 2003). CYP2B6 inducers (Table 3) are
typically ligands of either of these receptors, such as rifampicin and
barbiturates, or substances that activate both receptors (Faucette et
al., 2004, 2006). In human hepatocytes inducibility of CYP2B6 was
reported for cyclophosphamide (Gervot et al., 1999), artemisinine
(Burk et al., 2005), carbamazepine, efavirenz and nevirapine
(Faucette et al., 2007), metamizole (Saussele et al., 2007), the insect
repellent N,N-diethyl-m-toluamide DEET; (Das et al., 2008), and sever-
al statins (Feidt et al., 2010).
In humans CYP2B6 belongs to the minor hepatic P450s, contribut-
ing on average ~2–5% to the total hepatic P450 pool (Table 2), but it
exhibits ~300-fold variability of expression (Lang et al., 2001; Lamba
et al., 2003; Desta et al., 2007; Hofmann et al., 2008; Ohtsuki et al.,
2012). Expression in fetal liver appears to be considerably lower
with up to 36% of pediatric liver samples having undetectable levels
(Croom et al., 2009). According to this study CYP2B6 increases
about 2-fold within the ﬁrst month of life. Although most studies
did not ﬁnd a signiﬁcant sex difference in CYP2B6 expression, the
issue remains controversial as in some studies higher expression in
females versus males was found, depending on ethnicity (Lamba et
al., 2003). In another study 1.6-fold higher expression in female livers
was observed in all samples but there was no difference when sam-
ples from drug-treated donors were excluded (Hofmann et al.,
2008). Inﬂammation has also been recognized as an inﬂuential factor
for CYP2B6 expression, as shown by downregulation in human hepa-
tocytes in response to IL-6 and interferon γ (Aitken & Morgan, 2007).
CYP2B6 was detected at the level of RNA and protein in human
brain, where it was reported to be higher in samples of smokers and
alcoholics (Miksys et al., 2003), a result that awaits conﬁrmation.
Low levels of CYP2B6 transcripts were found in several extrahepatic
tissues including kidney (Aleksa et al., 2005), heart (Michaud et al.,
2010), placenta (Wang et al., 2010a), and in various tissues of the re-
spiratory tract including lung and nasal mucosa (Ding & Kaminsky,
2003). In contrast, expression in skin or keratinocytes (Du et al.,
2006) and intestine (Paine et al., 2006) appears to be low or absent
(Table 2).
4.2.2. Role of CYP2B6 in drug metabolism
The CYP2B6 substrate selectivity comprisesmany diverse chemicals,
including not only clinically used drugs but also a large number of
environmental chemicals (Table 3). Therapeutically important drugsmetabolizedmainly by CYP2B6 include the prodrug cyclophosphamide,
which is converted to the direct precursor of the cytotoxic metabolites,
phosphoramide mustard and acrolein, by 4-hydroxylation; the
non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz; the
atypical antidepressant and smoking cessation agent bupropion; the
antimalarial artemisinin; the anaesthetics propofol and ketamine;
the μ-opioid agonist methadone, and others (Zanger et al., 2007;
Turpeinen & Zanger, 2012). Suitable probe drugs for CYP2B6 include
S-mephenytoin N-demethylation and bupropion hydroxylation, of
which the latter one was shown to be more selective (Faucette et al.,
2000; Fuhr et al., 2007) and is nowmost often used. Another potentially
useful in vivo probe drug is efavirenz, based on in vitro investigations
(Ward et al., 2003; Desta et al., 2007). CYP2B6 also metabolizes the
N-demethylation of the recreational drug “ecstasy” (MDMA), which
leads to potentially neurotoxic metabolites (Kreth et al., 2000), and it
plays a minor role in nicotine metabolism (Yamazaki et al., 1999;
Yamanaka et al., 2005). Numerous studies have furthermore document-
ed an important role of CYP2B6 in themetabolism of pesticides and sev-
eral other environmental chemicals and pollutants (Hodgson & Rose,
2007), in particular the activating oxidation of organophosphorus in-
secticides to theirmore toxic oxonmetabolites. Examples are the organ-
ophosphorus insecticide, chlorpyrifos (Crane et al., 2012), the
insecticide and endocrine disruptor methoxychlor, and the extensively
used insect repellent DEET, among many others (Hodgson & Rose,
2007). Recent studies have revealed the crystal structure of CYP2B6 in
complex with various inhibitors, providing ﬁrst views into its active
site and ligand binding properties (Gay et al., 2010; Shah et al., 2011).
4.2.3. Genetic polymorphisms and functional impact
The CYP2B6 gene is extensively polymorphic with numerous vari-
ants in the coding and noncoding regions of the gene (Lang et al.,
2001; Lamba et al., 2003; Lang et al., 2004; Klein et al., 2005;
Zukunft et al., 2005; Zanger et al., 2007). The CYPalleles website cur-
rently lists 29 distinct star-alleles with variant amino acid sequence
or with proven functional effect. More than 30 SNPs code for amino
acid changes which occur in different combinations and additional
haplotype variants and SNPs not yet assigned to particular alleles
exist. The most common allele is CYP2B6*6 with two amino acid
changes Gln172His and Lys262Arg, in combination with other identi-
ﬁed changes mainly in the promoter. The *6 allele occurs with fre-
quencies between 15 and 60% across different populations (Table 1)
and is associated with 50 to 75% decreased hepatic liver protein ex-
pression (Lang et al., 2001; Lamba et al., 2003; Desta et al., 2007).
The major causal variant for decreased expression was identiﬁed as
the 15631G>T [Gln172His] polymorphism, which was shown to
cause incorrect splicing of the CYP2B6 pre-mRNA leading to a shorter
mRNA that lacks exons 4 to 6 (Hofmann et al., 2008). This polymor-
phism represents an example of a nonsynonymous variant leading
to major effects that are unrelated to the amino acid exchange but in-
stead to changes on the mRNA level (Zanger & Hofmann, 2008; Sadee
et al., 2011). Importantly, only appropriately designed RT-PCR assays
will detect the qualitative and quantitative mRNA changes associated
with this particular genetic variant (Hofmann et al., 2008). CYP2B6
genotyping by testing for 15631G>T as a marker of the *6 allele ap-
pears to be straightforward. However, it should not be forgotten
that this results in the detection of a mixture of related complex hap-
lotypes with additional upstream region SNPs (–1456T>C and
-750T>C) and the second nonsynonymous variant 18053A>G
[K262R]. Only marginal changes appear to be associated with the pro-
moter variants (Lamba et al., 2003; Hesse et al., 2004; Hofmann et al.,
2008), but differential functional effects conferred by the K262R
amino acid variant have been reported. The K262R variant (*4 allele,
frequency ~2–6%) was associated with higher activity towards several
substrates including bupropion (Kirchheiner et al., 2003), nicotine
(Johnstone et al., 2006), efavirenz (Rotger et al., 2007), artemether
(Honda et al., 2011), and selegiline (Watanabe et al., 2010).
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ethynylestradiol (Bumpus et al., 2005) and further studies indicated
altered active site topology of the variant resulting in more uncoupled
reaction kinetics (Bumpus & Hollenberg, 2008). In contrast cyclo-
phosphamide activation was found to be enhanced by the recombi-
nant Q172H variant but decreased by the K262R variant (Xie et al.,
2003; Ariyoshi et al., 2011; Raccor et al., 2012). These data strongly
emphasize the need to perform detailed genotyping of the involved
CYP2B6 variants in order to obtain conclusive results in particular
from in vivo studies. Further differential effects of the amino acid var-
iants were reported with respect to enzyme inactivation. In contrast
to the wild-type enzyme the recombinantly expressed K262R variant
was not inactivated by efavirenz, but both enzymes were irreversibly
inhibited by 8-hydroxyefavirenz (Bumpus et al., 2006). Lower suscep-
tibility to inhibition of the K262R variant and the *6 (Q172H/K262R)
double variant was also found with respect to sertraline and
clopidogrel and several other potent drug inhibitors of CYP2B6
(Talakad et al., 2009). Taken together, the low-expressor phenotype
of the 15631G>T variant is partially compensated for by higher spe-
ciﬁc catalytic activity at least for some substrates, which explains
some conﬂicting data regarding observations made in liver micro-
somes, heterologous expression systems, or studies in vivo. This also
appears to be the case for the *5 variant (25505C>T [R487C]) which
expresses very low levels of an apparently highly active enzyme
with bupropion (Lang et al., 2001) as well as efavirenz (Desta et al.,
2007), which explains why it was not associated with efavirenz phar-
macokinetics in patients (Burger et al., 2006).
Another important functionally deﬁcient allele is CYP2B6*18
(21011T>C [I328T]), which occurs predominantly in African subjects
with allele frequencies of 4–12% (Mehlotra et al., 2007; Li et al.,
2012b). The variant cDNA did not form a functional protein in
transfected mammalian cells tested with bupropione (Klein et al.,
2005) and lack of activity was also found in vitro for 7-EFC and selegiline
(Watanabe et al., 2010) as well as artemether (Honda et al., 2011). The
*18 allele is thus phenotypically a null allele. At least 12 additional null
or low-activity alleles have been described and analyzed with various
substrates (Lang et al., 2004; Klein et al., 2005; Rotger et al., 2007;
Watanabe et al., 2010; Honda et al., 2011). Although they are rather
rare in all investigated populations they may have profound effects on
drug metabolism if present in compound heterozygous genotypes e.g.
in combination with *6 or *18 (Rotger et al., 2007). The CYP2B6*22 allele
is a gain-of-function variant associated with increased transcription in
vitro (Zukunft et al., 2005) and with increased activity in vivo (Rotger
et al., 2007). It was shown that a –82T>C exchange alters the
TATA-box into a functional CCAAT/enhancer-binding protein binding
site that causes increased transcription from an alternative downstream
initiation site (Zukunft et al., 2005). Interestingly, the –82T>C polymor-
phism also confers synergistically enhanced CYP2B6 inducibility by the
PXR ligand rifampicin in human primary hepatocytes (Li et al., 2010).
4.2.4. Clinical impact of genetic variation
A major clinical role of CYP2B6 polymorphism was established in
HIV therapy, following the identiﬁcation of CYP2B6 as the major
enzyme responsible for 8-hydroxylation of efavirenz and its further
hydroxylation to 8, 14-dihydroxyefavirenz (Ward et al., 2003). The
potent ﬁrst-generation NNRTI of HIV-1is recommended as initial
therapy with two NRTIs in highly active antiretroviral therapy
(HAART) regimes, but patients with subtherapeutic plasma concen-
trations can develop resistance and treatment failure, whereas those
with too high plasma levels are at increased risk of CNS side effects,
which can lead to treatment discontinuation in a fraction of patients
(King & Aberg, 2008). Several CYP2B6 low activity alleles have been
associated with increased efavirenz plasma levels in numerous stud-
ies investigating HIV-infected adults and children. Homozygosity for
the 15631T [Q172H] variant is associated with several-fold higher
median efavirenz AUC compared to carriers of only one or noT-allele as shown in numerous clinical studies (see reviews King &
Aberg, 2008; Telenti & Zanger, 2008; Rakhmanina & van den Anker,
2010). Compound heterozygotes of 15631T and another low activity
allele (e.g. *11, *18, *27, *28) also predict high efavirenz plasma levels
(Rotger et al., 2007; Ribaudo et al., 2010). Three CYP2B6 polymor-
phisms, 15631G>T, 21011T>C and intron 3 rs4803419, were inde-
pendently associated with efavirenz pharmacokinetics at genome-
wide signiﬁcance (Holzinger et al., 2012). In addition to CYP2B6
polymorphism, CYP2A6 and CYP3A4/5 variants also inﬂuence clear-
ance, in particular when CYP2B6 is impaired (Arab-Alameddine et
al., 2009). The 15631T [Q172H] variant was furthermore associated
with increased neurotoxicity and other CNS side effects (Haas et al.,
2004; King & Aberg, 2008; Lubomirov et al., 2010; Ribaudo et al.,
2010; Maimbo et al., 2011) with highly active antiretroviral therapy
(HAART)-induced liver injury (Yimer et al., 2012), and with efavirenz
treatment discontinuation and the associated risk of developing drug
resistance (Ribaudo et al., 2006; Lubomirov et al., 2011; Wyen et al.,
2011). In prospective, genotype-based dose adjustment studies the
therapeutic dose of efavirenz could be successfully reduced and
CNS-related side effects decreased (Gatanaga et al., 2007; Gatanaga
& Oka, 2009). Using pharmacokinetic modelling and simulation it
was suggested that a priori dose reduction in homozygous CYP2B6*6
patients would maintain drug exposure within the therapeutic
range in this group of patients (Nyakutira et al., 2008).
In addition to efavirenz, CYP2B6 genotype also affects plasma levels of
the antiretroviral drug nevirapine (Penzak et al., 2007; Mahungu et al.,
2009). The impact of the 15631G>T polymorphism on nevirapine expo-
sure was conﬁrmed and quantiﬁed in a pharmacometric analysis of nevi-
rapine plasma concentrations from 271 patients genotyped for 198
SNPs in 45 ADME genes and covariates (Lehr et al., 2011). Moreover,
nevirapine-related cutaneous adverse events, which are most likely
MHC class I-mediated, were signiﬁcantly inﬂuenced by CYP2B6 polymor-
phismwhile hepatic side effects, most likelyMHC class II-mediated, were
unaffected by CYP2B6 (Yuan et al., 2011).
While efavirenz pharmacokinetics appears to be largely explained by
low expression of CYP2B6*6 in liver, other substrates may be additionally
inﬂuenced by altered catalytic functions of CYP2B6 protein variants as
outlined above. Bioactivation of thewidely used anticancer and immuno-
suppressant prodrug cyclophosphamide to 4-hydroxycyclophosphamide
is highly variable in cancer patients and has been attributed mainly to
CYP2B6 in vitro and in vivo with contributions from CYP2C19 and
CYP3A4 (Chang et al., 1993; Raccor et al., 2012). There is growing evi-
dence that cyclophosphamide bioactivation and response to therapy de-
pend on CYP2B6 genotype (Xie et al., 2006; Nakajima et al., 2007; Rocha
et al., 2009; Bray et al., 2010; Melanson et al., 2010; Yao et al., 2010b;
Raccor et al., 2012). As mentioned above, allele-effects, particularly for
*4 and *6, appear to differ for cyclophosphamide, most likely due to
substrate-speciﬁc effects of amino acid substitutions (Ariyoshi et al.,
2011; Raccor et al., 2012). Furthermore, the *5 (R487C) variant, not
found to be related to efavirenz disposition, was signiﬁcantly associated
with lower rate of overall toxicity and higher rate of relapse in patients
who received high dose CPA treatment (Black et al., 2012). However,
data concerning cyclophosphamide from in vivo and in vitro studies are
so far not consistent. In part this may be explained by lack of consistency
in allele deﬁnition and genotype information among studies (Helsby &
Tingle, 2011).
CYP2B6 allele variants were also investigated in the context of the
synthetic μ-opioid receptor agonist, methadone, which is metabo-
lized by CYPs 3A4/5, 2B6, and 2D6, and used as a maintenance treat-
ment for opioid addiction. In *6/*6 carriers (S)-methadone plasma
levels were increased leading to potentially higher risk of severe
cardiac arrhythmias and methadone associated deaths (Crettol et
al., 2005; Eap et al., 2007; Bunten et al., 2011). Methadone dose re-
quirement for effective treatment of opioid addiction was shown
to be signiﬁcantly reduced in carriers of this genotype (Levran et
al., 2011).
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not yet been fully explored but an increasing number of studies
suggest clinical relevance for different drug substrates. Importantly,
the relationship between CYP2B6 genotype and in vivo drug metabo-
lism function is complex due to the combined effects of the involved
variants on both expression and catalytic properties, the latter of
which additionally depend on the substrate.
4.3. Subfamily CYP2C: CYP2C8, CYP2C9, CYP2C18, CYP2C19
4.3.1. Regulation and variability of gene expression
The human CYP2C subfamily consists of the four highly homologous
genes CYP2C18-CYP2C19-CYP2C9-CYP2C8 which are localized in this
order (from centromere to telomere) in a ~390 kb gene cluster on chro-
mosome 10q23.3. Although CYP2C18 mRNA is highly expressed in liver,
the transcript is not efﬁciently translated into protein and does notmake
signiﬁcant contributions to drug metabolism. CYP2C9 is the highest
expressed member being expressed at similar or even higher protein
levels compared to CYP3A4, while CYP2C8 and CYP2C19 are expressed
at ~2-fold and 10-fold lower levels (Coller et al., 2002; Koukouritaki et
al., 2004; Rettie & Jones, 2005; Naraharisetti et al., 2010; Ohtsuki et al.,
2012). The dramatic expression difference between CYP2C9 and 2C19
was found to be at least in part due to the inability of the CYP2C19 pro-
moter to be activated by HNF4α, despite the presence of similar
HNF4α binding sites in both gene promoters (Kawashima et al., 2006).
In addition to HNF4α, constitutive expression of the CYP2C genes in
liver requires several other liver-enriched transcription factors including
HNF3γ and C/EBPα (Chen &Goldstein, 2009) and the liver-enriched fac-
tor GATA-4 (Mwinyi et al., 2010b). All three expressed CYP2C enzymes
are inducible by ligands of the PXR/CAR, glucocorticoid (GR) and vitamin
D (VDR) nuclear receptor pathways through different response elements
in their 5′-ﬂanking regions (Chen & Goldstein, 2009; Jover et al., 2009;
Helsby & Burns, 2012). However, the genes show different relative in-
ducibility. CYP2C8 is the most strongly inducible member, e.g. by statins
(Feidt et al., 2010). Although distal PXR/CAR binding sites have been
identiﬁed, the precise reason for the high inducibility of CYP2C8 has
not been elucidated. Maximal induction of CYP2C9 requires cross-talk
between distal CAR/PXR sites and proximal HNF4α binding sites in the
CYP2C9 promoter which may be mediated by a mega-complex of
HNF4α-associated cofactors including PGC-1α, SRC-1, and NCOA6
(Jover et al., 2009). Recently regulation of CYP2C19 (Mwinyi et al.,
2010a) and CYP2C9 (Mwinyi et al., 2011) transcription by estrogen
receptor alpha (ERα)-ligands was shown to be mediated by newly dis-
covered response elements at ~150 bp upstream of the transcriptional
start site, probably contributing to the known inhibition of these
enzymes by oral contraceptives.
In a humanized CYP2C18/CYP2C19 transgenic mouse line only
CYP2C19, but not CYP2C18 was expressed in liver to yield a catalyti-
cally active enzyme. Interestingly, adult male mice expressed much
higher CYP2C18 and CYP2C19 mRNA levels in liver and kidney com-
pared with female mice (Löfgren et al., 2009). This appears to reﬂect
the generally more pronounced sex effects on expression in mice
compared to humans. Sex differences of human CYP2C9 and
CYP2C19 have been investigated in only a few studies which so far
do not seem to support the existence of marked sex-biased activity
(Gandhi et al., 2004). At lower levels functional CYP2C enzymes are
also expressed in extrahepatic tissues, e.g. in human small intestine
and in cardiovascular tissues (Delozier et al., 2007). Together with
CYP3A, the CYP2Cs represent the major intestinal CYPs, accounting
for ~80% and 18%, respectively, of total immunoquantiﬁed CYPs
(Paine et al., 2006; Thelen & Dressman, 2009).
4.3.2. Role of CYP2C enzymes in drug metabolism
Given the strong relatedness in DNA and protein sequence (>82%)
and common mechanisms of transcriptional regulation of the CYP2C
enzymes, it is surprising how unique each enzyme is in terms ofsubstrate speciﬁcity and role in drug metabolism (Table 3). The
major enzyme CYP2C9 accepts weakly acidic substances including
the anticoagulant warfarin, the anticonvulsants phenytoin and
valproic acid, the angiotensin receptor blockers candesartan and
losartan, oral antidiabetics like glibenclamide and tolbutamide, and
most nonsteroidal anti-inﬂammatory drugs (NSAIDs; (Lee et al.,
2002). Commonly used substrates for CYP2C9 phenotyping are
diclofenac and tolbutamide. The CYP2C9 enzyme also metabolizes en-
dogenous substances, in particular arachidonic acid and some ste-
roids. The crystal structure of CYP2C9 has been resolved both
unliganded and in complex with warfarin showing evidence for an
additional substrate binding pocket (Williams et al., 2003). CYP2C9
is inhibited by several substances (Table 3) and this can be clinically
important as in the case of warfarin treatment (Lu et al., 2008).
CYP2C8 is mainly responsible for the metabolism of the antidiabetics
rosiglitazone and pioglitazone, the antiarrhythmic amiodarone, the nat-
ural anticancer drug paclitaxel, and the antimalarial amodiaquine,
which is now commonly used as a selective marker activity. In addition
to amodiaquine, CYP2C8 has a major role in metabolizing other antima-
larials such as chloroquine and dapsone (Kerb et al., 2009). Additional
drugs metabolized primarily by CYP2C8 include some retinoic acid
drugs used in acne and cancer treatment. Some overlap in substrate
speciﬁcity with CYP2C9 occurs, e.g. in the case of ibuprofen and others
(Table 3; Goldstein, 2001; Lai et al., 2009). The clinical signiﬁcance of
CYP2C8 inhibition became apparent after its involvement in fatal drug
interactions was described, which were in part due to its potent inhibi-
tion by gemﬁbrozil acyl-glucuronide, ultimately leading to rhabdomyol-
ysis (Backman et al., 2002; Ogilvie et al., 2006). Additional potent
CYP2C8 inhibitors at clinically relevant concentrations have meanwhile
been described (Lai et al., 2009).
CYP2C19 was the ﬁrst CYP2C enzyme to be discovered by its
marked genetic polymorphism resulting in the S-mephenytoin PM
and EM phenotypes (Küpfer & Preisig, 1984). The CYP2C19 enzyme
was later shown to be the major enzyme for the inactivating metab-
olism of proton pump inhibitors (PPI) including omeprazole and
pantoprazole, and for the metabolic activation of the anticoagulant
clopidogrel to the active 2-oxo metabolite (Hulot et al., 2006; Kazui
et al., 2010; Dansette et al., 2011; Boulenc et al., 2012). CYP2C19 has
also a prominent role in the metabolism of several antidepressants
of the ﬁrst and second generation (Brøsen, 2004). Endogenous
substrates of CYP2C19 include progesterone and melatonin (Table 3).
4.3.3. Genetic polymorphisms and functional impact
4.3.3.1. CYP2C8. Apart from rare variants with no (*5, *7), reduced (*8)
or unknown activity, three alleles with amino acid changes, CYP2C8*2
and *3 (Dai et al., 2001), and *4 (Bahadur et al., 2002) aremore common
and have potential clinical relevance (Table 1). CYP2C8*2 [I269F] has
been found practically only in Africans and African Americans at fre-
quencies of ~10 to 22%. Slower conversion of the antimalarial drug
amodiaquine to its metabolite N-desethylamodiaquine (DEAQ) in
carriers of CYP2C8*2 has been reported (Li et al., 2002; Parikh et al.,
2007). The heterologously expressed 2C8.2 variant had 2-fold lower
intrinsic clearance for paclitaxel due to increased Km. CYP2C8*3
[R139K+K399R] occursmore frequently inwhite subjects but is almost
absent in Africans and Asians. The CYP2C8.3 variantwas initially shown
to have reduced metabolic activity toward arachidonic acid (~40%) and
paclitaxel (~80%) (Dai et al., 2001). Amore recent comparison of protein
variants expressed in yeast revealed lower activity of 2C8.2, 2C8.3 and
2C8.4 and altered IC50 values towards inhibitors compared to 2C8.1
(Gao et al., 2010). Some functional effects of CYP2C8*3 appear to be sub-
strate dependent, e.g. for repaglinide and rosiglitazonehighermetabolic
capacity of this variantwas observed (Daily & Aquilante, 2009). Similar-
ly, a recent study showed 40% increased activity with pioglitazone as
substrate of liver microsomes genotyped as CYP2C8*3/*3 compared to
*1/*1 (Muschler et al., 2009).
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um (LD) between the CYP2C gene polymorphisms, due to their close
distances. In particular CYP2C8*3 is in partial LD to CYP2C9*2, which
may account in part for the association between CYP2C8*3 and
CYP2C9*2 and *3 alleles with reduced clearance of ibuprofen
(Garcia-Martin et al., 2004). CYP2C8 pharmacogenetics has recently
been reviewed (Daily & Aquilante, 2009).
4.3.3.2. CYP2C9. Among the 35 distinct alleles listed on the CYPalleles
website, the initially discovered alleles *2 [R144C] and *3 [I359L] are
the best investigated ones (Goldstein, 2001; Rettie & Jones, 2005). The
global MAFs of two variants are ~7% and ~4%, respectively, but their fre-
quency in African and Asian populations is generally low, whereas *2 is
present in >10% in some Caucasian populations (Table 1). The replace-
ment of the positively charged arginine by cysteine in the 2C9.2 variant
appears to affect the interaction of the protein with POR (Crespi &
Miller, 1997). Expressed mutant CYP2C9.2 and CYP2C9.3 proteins
have reduced intrinsic clearance, although the degree of activity reduc-
tion appears to depend on the particular substrate. For example, the
Vmax/Km values of yeast-expressed 2C9.1 and 2C9.2 variants for
seven different substrates including diclofenac, tolbutamide and
piroxicam varied from 3.4-fold to 26.9-fold (Takanashi et al., 2000).
The 359Leu variant had higher Km values than did the wild-type for
all the reactions studied. Remarkably, thewidely usedmarker substrate
diclofenac was not a sensitive substrate to detect the *2/*3 activity
difference either in this study or in vivo (Shimamoto et al., 2000). Com-
pared to the *2 allele the *3 allele is more severely affected in its activity
which can be 70–90% reduced for some substrates. In vivo, this results
in clearance reductions of more than 70% in *3/*3 homozygotes and in
about half of the clearance for heterozygotes. Other more rare alleles
with decreased function include *5, *6, *8, and *11, although *8was rec-
ognized as the most frequent CYP2C9 variant among African Americans
(Scott et al., 2009). Promoter variantsmay contribute to expression var-
iability as shown in a study which resequenced the upstream region
and investigated numerous known and novel variants using a reporter
gene assay (Kramer et al., 2008). On the other hand a large
resequencing study in 400 Chinese subjects identiﬁed only 3 novel var-
iants of unknown functional signiﬁcance, indicating that probably most
of the genetic variation in CYP2C9 is already known, at least among
Asians (Xiong et al., 2011).
4.3.3.3. CYP2C19. The CYP2C19 or “S-mephenytoin polymorphism”
was discovered during the early 1980s and was since then established
as one of the clinically most relevant P450 polymorphisms (Küpfer &
Preisig, 1984; Wrighton et al., 1993; De Morais et al., 1994a; Meyer &
Zanger, 1997; Goldstein, 2001; Rosemary & Adithan, 2007). The exis-
tence of fairly common null alleles explains the large variability and
strong phenotype–genotype correlations found for CYP2C19. About
2 to 5% of white and black populations but up to ~25% of Asians are
CYP2C19 PMs (Table 1). The two most important null alleles are
CYP2C19*2, which occurs almost exclusively in Caucasians, and
CYP2C19*3, which occurs primarily in Asians. The causal mutation of
*2 is located in exon 5 and leads to aberrant splicing (De Morais et
al., 1994b), whereas that of *3 in exon 4 creates a premature stop
codon (De Morais et al., 1994a). A further clinically relevant variant
is the promoter variant –806C>T (*17) which appears to increase ex-
pression and activity toward mephenytoin and omeprazole by a still
unclear mechanism (Sim et al., 2006). Additional rare null alleles
CYP2C19*4–*8 and variants with unknown phenotypic penetrance
are listed on the CYPalleles nomenclature website.
4.3.4. Clinical impact of genetic variation
4.3.4.1. CYP2C8. Drug interaction studies support the importance of
CYP2C8 for the hypoglycemic agent repaglinide. However, the impact
of CYP2C8 pharmacogenetics on repaglinide pharmacokinetics andclinical consequences is unclear. Some pharmacokinetic studies
reported that individuals heterozygous for CYP2C8*3 showed higher
drug clearance and up to 60% lower plasma levels of repaglinide com-
pared with CYP2C8*1 carriers (Niemi et al., 2003; Rodríguez-Antona
et al., 2008). Recently, a healthy volunteer study indicated that
CYP2C8*3 did not affect the pharmacokinetics as well as pharmacody-
namic parameters like changes in insulin and glucose concentration
of repaglinide (Tomalik-Scharte et al., 2011). Confounding by
genetic variants of the organic anion transporting polypeptide 1B1
(SLCO1B1), which mediates the uptake of repaglinide into cells,
could be excluded in this study. CYP2C8 variants were reported to
moderately alter pharmacokinetics and effects of PPAR-γ agonists
such as rosiglitazone and pioglitazone (Kirchheiner et al., 2006;
Tornio et al., 2008; Yeo et al., 2011) but this contention is also contro-
versially discussed by others (Pedersen et al., 2006).
The same conclusion is true for the anticancer drug paclitaxel fre-
quently used in treatment of women with ovarian or breast cancer
(Henningsson et al., 2005; Bergmann et al., 2011a, 2011b; Leskelä et
al., 2011). Whether subjects carrying CYP2C8 variants are at increased
risk of amodiaquine-related severe ADRs is also still a matter of
discussion (Kerb et al., 2009).
4.3.4.2. CYP2C9. Genetic variation in CYP2C9 is a recognized factor for
ADRs as many of its drug substrates have a narrow therapeutic index.
Numerous studies demonstrated the clinical signiﬁcance of the
CYP2C9*2 and *3 polymorphisms for most drug substrates mentioned
above. Due to their common occurrence in Caucasians, there are
about 1 to 2% of homozygous (*2/*2, *3/*3) and hemizygous (*2/*3)
carriers that are at risk to experience more dramatic effects, but
even for the heterozygous carriers higher incidence of ADRs were
reported. This includes, for example, hypoglycaemia as a result from
treatment with hypoglycaemic drugs (Holstein et al., 2005; Xu et al.,
2009), gastrointestinal bleeding from NSAIDs (see below) and serious
bleedings from anticoagulant treatment. Vitamin K antagonists such
as warfarin, acenocoumarol, and phenprocoumone are commonly
used to prevent thrombosis in several situations. The anticoagulant
warfarin is probably the most thoroughly studied clinical application
of CYP2C9 pharmacogenetics. In addition to the vitamin K epoxide
reductase complex subunit 1 (VKORC1), variants of CYP2C9 affect
warfarin dosing and response (Jonas & McLeod, 2009). However its
contribution to anticoagulant response is rather low. In a study of
539 white patients on steady-state warfarin therapy 9% of variability
in warfarin dose could be explained by CYP2C9 variants, compared to
25% by variants of VKORC1 (Rieder et al., 2005). Between 50 and 60%
of the variability in maintenance dose of warfarin in Caucasians could
be explained by variants of CYP2C9 and VKORC1 in combination with
other patient factors (e.g. body size, age; (Klein et al., 2009). Different
distribution of CYP2C9 and VKORC1 variants as a function of ancestry
resulted in highest dose requirement of warfarin in Africans com-
pared to Asians requiring lowest doses. In 2007 pharmacogenetic in-
formation on CYP2C9 and VKORC1 genetic polymorphisms as a
predictor of response was included in the warfarin labeling by the
FDA, and was revised in 2010 to include speciﬁc dosing recommenda-
tions. Currently various pharmacogenetics-guided warfarin dosing al-
gorithms are available (Jonas & McLeod, 2009; Schwab & Schaeffeler,
2011). Interindividual dosage variation for the anticoagulants aceno-
coumarol (Teichert et al., 2009) and phenprocoumon (Teichert et al.,
2011) has also been associated with CYP2C9 genotype at genome-
wide signiﬁcance.
The inﬂuence of CYP2C9 polymorphisms on the metabolism of
ﬁrst- and second generation sulfonylurea hypoglycaemic drugs
(e.g., glibenclamide, tolbutamide, glyburide, glimepiride) has been
well-established by several studies with consequences on pharmaco-
kinetics and in part on therapeutic response (e.g., HbA1C decrease,
secondary failure of therapy, hypoglycemic events; (Manolopoulos
et al., 2011). For example, type 2 diabetes mellitus patients responded
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of CYP2C9 as compared to those with normal genotype (Surendiran et
al., 2011).
CYP2C9 polymorphism affects the metabolism of several NSAIDs,
which is of increasing importance in aging populations, due to
dose-dependent ADRs (He et al., 2011). Association of NSAID expo-
sure and risk for gastrointestinal bleeding with CYP2C9 genetic vari-
ants has been reported by several studies (Pilotto et al., 2007;
Carbonell et al., 2010). However, due to limited data available and
the fact that the published studies show substantial methodological
limitations current evidence is still controversial (Estany-Gestal et
al., 2011).
Finally, the fact that CYP2C9 catalyzes arachidonic acid epoxygenation
and that it is expressed in endothelial cells suggested a role in ischemic
heart disease and vascular homeostasis (Chehal & Granville, 2006). How-
ever in three independent studies totaling more than 52,000 individuals,
no association between CYP2C9*2 and *3 polymorphisms and risk of
atherosclerosis, ischemic vascular disease or death after ischemic heart
disease was found (Kaur-Knudsen et al., 2009a).
4.3.4.3. CYP2C19. The clinical signiﬁcance of CYP2C19 has been extensive-
ly documented (Goldstein, 2001; Desta et al., 2002; Furuta et al., 2007;
Rosemary & Adithan, 2007; Lee, 2013). The effect of the CYP2C19 poly-
morphismonH. pylori eradication therapy in patientswith ulcers is a spe-
cial but intriguing example of clinical pharmacogenetics (Furuta et al.,
2004; Klotz, 2006). The commoneradication strategy involves application
of different antibiotics (e.g., amoxicillin, clarithromycin, metronidazole),
together with a proton pump inhibitor, which contributes to accelerated
ulcer healing and increases effectiveness of the antibiotics. Since
CYP2C19 contributes signiﬁcantly to the metabolism of the PPIs omepra-
zole, lansoprazole, and pantoprazole and to minor extent to the metabo-
lism of rabeprazole, pharmacokinetics, the PPI-induced increase in
intragastric pH and treatment outcome depend on CYP2C19 genotype
(Furuta et al., 1998; Klotz et al., 2004; Furuta et al., 2007). For instance,
PM subjects showed 4- to 15-fold increased AUC values for omeprazole
and lansoprazole compared with EMs resulting in signiﬁcantly higher H.
pylori eradication rates compared to EMs. Accordingly, the PPI-induced
increase in intragastric pH depends on the CYP2C19 polymorphism. In
several studies with PPI based dual, triple and quadruple therapy in Asia
and Europe it was shown that PM subjects beneﬁt from their lower me-
tabolism rate because their drug levels stay higher for a longer time
resulting in a stronger acid inhibition and higher intragastric pH (Furuta
et al., 2007; Yang & Lin, 2010). Since PPI are used also for the treatment
of non-ulcer dyspepsia, reﬂux oesophagitis, gastroesophageal reﬂux
disease (GERD), the Zollinger–Ellison syndrome, and prevention and
treatment of NSAID-associated damage, healing rates of these diseases
are also impacted by CYP2C19 genotype (Schwab et al., 2004, 2005). The
CYP2C19 PM genotype does however not appear to be a risk factor for
omeprazole-associated visual disorders (Lutz et al., 2002).
Pharmacokinetic effects associated with CYP2C19 genotype have
also been reported for several antidepressants, including clomipra-
mine (Nielsen et al., 1994), citalopram (Tai et al., 2002), amitriptyline
(Steimer et al., 2005), moclobemide (Yu et al., 2001), as well as for
benzodiazepines like diazepam (Bertilsson et al., 1989) and clobazam
(Kosaki et al., 2004). Moreover, the CYP2C19 gene has substantial im-
pact on the pharmacokinetics of the antifungal agent voriconazole
and its interaction with other drugs (Mikus et al., 2011) and of the
antimalarial drug proguanil (Kerb et al., 2009). Although pharmacoki-
netic alterations were sometimes related to ADRs, an inﬂuence of
CYP2C19 genotype on clinical pharmacodynamic outcome for most
of these drugs remains so far controversial.
Important recent studies investigated CYP2C19 as a genetic
determinant of the efﬁcacy of the platelet aggregation inhibiting
thienopyridine, clopidogrel (Plavix). Both, treatment and prevention
of atherothrombotic events after percutaneous coronary revascular-
ization in patients with coronary artery disease with clopidogrel iscomplicated because a signiﬁcant proportion of patients is resistant and
experiences insufﬁcient platelet inhibition resulting in cardiovascular
(re-)events including stent thrombosis (Zuern et al., 2010). Numerous
clinical studies have conﬁrmed that CYP2C19 PMs have signiﬁcantly
lower anticoagulation effect of clopidogrel,which is associatedwith an in-
creased risk of major adverse cardiovascular events (Collet et al., 2009;
Mega et al., 2009; Simon et al., 2009; Soﬁ et al., 2011). Already in 2009,
the FDA added a Boxed Warning to the label for Plavix alerting patients
and health care professionals that the drug can be less effective in genet-
ically determined CYP2C19 PMs. However, recent meta-analyses drew an
inconsistent picture. No signiﬁcant or consistent inﬂuence of CYP2C19 ge-
notype on the clinical efﬁcacy of clopidogrel was found in one analysis
(Bauer et al., 2011), associationwith clopidogrel metabolic concentration
and platelet reactivity responsiveness but no overall associationwith car-
diovascular events in another one (Holmes et al., 2011), while the most
recent study, which analyzed 16 clinical studies, conﬁrmed signiﬁcant as-
sociations with major cardiovascular endpoints, i.e. increased risk of car-
diac death,myocardial infarction, and stent thrombosis (Jang et al., 2012).
Several clinical studies investigated the clinical impact of the
gain-of-function allele CYP2C19*17 (Zabalza et al., 2011). With
clopidogrel, no association with platelet aggregation was found
(Geisler et al., 2008) while another study reported increased risk of
bleeding events (Sibbing et al., 2010). The homozygous *17/*17 geno-
type has been found to accelerate omeprazole metabolism resulting
in subtherapeutic drug exposure (Baldwin et al., 2008). In another ex-
ample, homozygous CYP2C19*17 genotype was associated with
lower serum concentration of escitalopram, which might imply an
increased risk of therapeutic failure (Tai et al., 2002). Moreover, treat-
ment outcome of tamoxifen in postmenopausal breast cancer women
has been associated with the CYP2C19*17 allele, although the magni-
tude of effect appears to be considerably smaller compared to loss of
function alleles (Schroth et al., 2007; Li-Wan-Po et al., 2010). Howev-
er, not all studies have identiﬁed a signiﬁcant effect of CYP2C19*17
(Kurzawski et al., 2006; Ohlsson Rosenborg et al., 2008).
4.4. Subfamily CYP2D: CYP2D6
4.4.1. Regulation and variability of gene expression
CYP2D6 is the only protein-coding gene of the CYP2D subfamily.
The CYP2D locus on chromosome22q13.1also harbors twopseudogenes,
CYP2D7 and CYP2D8P (Kimura et al., 1989; Heim & Meyer, 1992).
CYP2D7 is expressed as mRNA in liver (Endrizzi et al., 2002), but the
presence of an insertion in the ﬁrst exon disrupts the reading frame,
preventing expression of protein. In contrast, CYP2D8P is a true pseudo-
gene which has accumulated several gene-disrupting mutations. Be-
cause CYP2D6 is considered to be essentially a noninducible gene not
signiﬁcantly inﬂuenced by smoking, alcohol consumption or sex (Bock
et al., 1994; Glaeser et al., 2005), its transcriptional regulation has not
been studied very thoroughly. It should be mentioned, however, that
phenotypically determined induction by rifampicin in vivowas reported
(Caraco et al., 1997). An initial promoter analysis revealed the presence
of a positiveDR-1 elementwhichbound and responded toHNF4αwhich
was antagonized by COUP-TF-I. It was concluded that the balance be-
tween HNF4α and COUP-TF-I may contribute to expression variability
(Cairns et al., 1996). HNF4α also mediates downregulation of CYP2D6
during inﬂammation by nitric oxide through the same proximal DR-1
site (Hara & Adachi, 2002). The regulation of CYP2D6 byHNF4αwas fur-
ther investigated in a CYP2D6-humanized transgenic mouse line which
expressed CYP2D6 protein in the liver, intestine, and kidney (Corchero
et al., 2001). Conditional inactivation of the HNF4α gene in this mouse
line decreased debrisoquine 4-hydroxylase activity by more than 50%
demonstrating that HNF4α regulates CYP2D6 activity in vivo. The inﬂu-
ence of HNF4α on CYP2D6 activity in vivowas further shown in a recent
population-based polymorphism study which showed that the rare
HNF4α variant G60D was unable to bind and activate the CYP2D6 pro-
moter (Lee et al., 2008b).
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to person mainly due to its genetic polymorphism (Zanger et al.,
2001). A recent quantitative comparison of hepatic CYP2D6 protein
by Western blot and mass spectrometric analysis demonstrated com-
parability of the results which ranged from undetectable in genetic
PMs up to ~70 pmol/mg of microsomal protein in carriers of three
alleles (Langenfeld et al., 2009). CYP2D6 and the CYP2D7 pseudogene
are found at low mRNA levels in most extrahepatic tissues (Table 2),
and expression of protein has been shown in the gastrointestinal tract
(Glaeser et al., 2005) and in different areas of the human brain
(Table 2; Siegle et al., 2001; Miksys et al., 2002; Gaedigk et al.,
2005; Dutheil et al., 2009; Ferguson & Tyndale, 2011). At the RNA
level, CYP2D6 expression is characterized by the occurrence of nu-
merous splice variants. However, with the exception of the effect of
polymorphic splice variants (see below) the functional signiﬁcance
of alternative splicing of CYP2D6 pre-mRNA has not been clariﬁed.
In foetal liver CYP2D6 is virtually undetectable but expression surges
within hours after birth (Cresteil, 1998). Investigation of CYP2D6 and
CYP3A4 activity in healthy infants by using dextromethorphane as
probe drug revealed that the CYP2D6-dependent O-demethylation
activity was detectable and concordant with genotype by 2 weeks
of age and showed no relationship with gestational age, whereas
the CYP3A4-dependent N-demethylation developed more slowly
over the ﬁrst year of life (Blake et al., 2007). In a large (n=222) set
of pediatric liver samples it was found that gestational age inﬂuenced
CYP2D6 protein expression and activity in prenatal samples whereas
postnatal samples were inﬂuenced by age and genotype (Stevens et
al., 2008).
4.4.2. Role of CYP2D6 in drug metabolism
The number of drugs metabolized primarily by CYP2D6 is very large
in comparison to its relatively minor expression in liver and includes
~15–25% of all clinically used drugs from virtually all therapeutic
classes, like antiarrhythmics (e.g. propafenone, mexiletine, ﬂecainide),
tricyclic and second generation antidepressants (e.g. amitriptyline,
paroxetine, venlafaxin), antipsychotics (aripiprazole, risperidone), β-
blockers (bufuralol, metroprolol), aswell as anti-cancer drugs, in partic-
ular the selective estrogen receptormodiﬁer (SERM) tamoxifen, several
opioid analgesics including codeine and tramadol, and many others
(Table 3; Zanger et al., 2008; Stingl et al., 2012). Several highly selective
test drugs have been used to determine the CYP2D6 drug oxidation
phenotype, including debrisoquine, dextromethorphan, metoprolol,
sparteine, and tramadol (Frank et al., 2007). Endogenous biotransfor-
mations include 5-methoxyindolethylamine O-demethylase (Yu et al.,
2003a) and regeneration of serotonin from 5-methoxytryptamine (Yu
et al., 2003b). CYP2D6 is also prone to inhibition by numerous com-
pounds that need not be substrates but bind to the enzyme with high
afﬁnity, e.g. quinidine or methadone (Gelston et al., 2012; Table 3).
Some of these inhibitors are strong enough to change the apparent
phenotype of the patient, a phenomenon known as phenocopying.
The structure–activity relationships for CYP2D6 substrates and inhibi-
tors were useful to develop pharmacophore models (Lewis et al.,
2004). The crystal structure of the CYP2D6 protein has been resolved
yielding further insights into the active site and the chemical require-
ments for binding and catalysis (Rowland et al., 2006).
4.4.3. Genetic polymorphisms and functional impact
The CYP2D6 polymorphism is historically the best studied and one
of the most intriguing examples of pharmacogenetics. CYP2D6 shows
the greatest impact of genetic polymorphism among all major drug
metabolizing CYPs, due to its wide spectrum of genetic variants
(from null alleles to several-fold gene ampliﬁcation), comparably lit-
tle inﬂuence by environmental and nongenetic factors, and its
extraordinarily broad substrate spelectivity. Initial evidence for
CYP2D6 genetic polymorphism came from population and family
pharmacokinetic studies in the 1970's which showed that deﬁcientdebrisoquine 4-hydroxylation (Mahgoub et al., 1977) and sparteine
N-oxidation (Eichelbaum et al., 1979) occurs in 5 to 10% of European
Caucasians as a monogenic recessive trait later shown to be the same
for the two drugs and for many others that are polymorphically me-
tabolized. In ethnicities other than Caucasian the deﬁciency occurs
at much lower frequency (Gaedigk, 2000). The molecular studies
that followed were reviewed previously (Meyer & Zanger, 1997;
Zanger et al., 2004; Ingelman-Sundberg, 2005). Currently 105 distinct
alleles and a large number of allele variants are listed on the
CYPalleles website, many of them leading to absent or nonfunctional
protein, or to decreased or increased expression (Table 1). Genotype–
phenotype correlation analysis studies in Caucasians phenotyped
with the probe drugs sparteine or debrisoquine have clearly demon-
strated the impact of genetic polymorphism on CYP2D6 function in
vivo (Fig. 2; Sachse et al., 1997; Griese et al., 1998; Raimundo et al.,
2004).
In Caucasians the most frequent null alleles are the CYP2D6*4 al-
leles, which all harbor a consensus splice site mutation (1846G>A)
that leads to absence of detectable protein in the liver. The collective
CYP2D6*4 allele frequency among Caucasians is about 20 to 25%, ac-
counting for 70 to 90% of genetically determined PMs (Sachse et al.,
1997; Griese et al., 1998). The virtual absence of the *4 allele in
Asian, African, and South American populations explains the low inci-
dence of the PM phenotype in these populations, whereas African-
Americans have an intermediate frequency. The CYP2D6 gene dele-
tion allele *5 is present at a frequency of 3 to 5% in most populations.
The null alleles *3 and *6 are present at frequencies of ~1–3% in Cau-
casians whereas most other null alleles are even rarer. Nevertheless,
collectively the low frequency alleles make a signiﬁcant contribution
to phenotype. Heterozygous carriers of one defective and one normal
allele of CYP2D6 tend to have a lower median enzyme activity, which
is overlapping with that of carriers of two functional alleles (Fig. 2).
A separate phenotype model has been termed intermediate
metabolizer (IM), which occurs in all major races, but interestingly
the causative mutations are different. About 10 to 15% of Caucasians
are carriers of one partially defective allele (e.g. *41, *9, *10) in com-
bination with another partially defective or null allele such as *4,
resulting in a distinct phenotypic subgroup with compromised spar-
teine oxidation capacity (Fig. 2). The mechanism of the *41 allele,
which is more common among Caucasians, has been studied in detail
and an intron 6 SNP that leads to erroneous splicing resulting in only
a fraction of correctly spliced mRNA has been shown to be responsi-
ble for the low activity in vitro and in vivo (Toscano et al., 2006). In
Africans and Asians other partially defective alleles termed *17 and
*10, respectively, are prevalent. The *17 allele is present at frequen-
cies of up to 30% in Africans (Wennerholm et al., 2002) and the *10
variant occurs at up to 50% in Asians (Sakuyama et al., 2008). Due
to their high frequencies, the partial activity conferred by these alleles
leads to a shift of the metabolic drug oxidation capacity towards
lower values which has clinical relevance (Kitada, 2003).
A large number of structural variations exists at the CYP2D locus
(Schaeffeler et al., 2003; Gaedigk et al., 2010). Unequal crossing
over between the highly homologous genes involving a certain repet-
itive sequence also present in the c-myc gene lead to variants with de-
leted, duplicated, or otherwise recombined genes. CYP2D6 gene
duplications were ﬁrst identiﬁed in combination with the functional
*2 allele (Bertilsson et al., 1993; Johansson et al., 1993; Johansson &
Ingelman-Sundberg, 2008) and later shown to occur also with other
alleles including *1, *4, *6, *10, *17, *29, *35, *41, *43, *45. This is im-
portant because not all duplications comprise functional genes,
which complicates phenotype prediction (Schaeffeler et al., 2003;
Gaedigk et al., 2012). The overall frequency of the gene duplications
in Caucasians is between 1 and 5% whereas in some Arabian, Eastern
African and Paciﬁc populations it can reach 10 and even up to 50% and
more. It was hypothesized, therefore, that the striking preference of
CYP2D6 for plant alcaloids found in food of some of these ethnicities
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The presence of the pseudogenes, structural variants, and numer-
ous SNPs at the CYP2D locus requires particular cautiousness in the
design of genotyping assays. Coampliﬁcation of pseudogenes, unex-
pected recombination events, and failure to account for important
variants, for example due to ethnic variation can lead to erroneous in-
terpretation of genotype. Numerous genotyping assays and strategies
were developed which, due to the complexity of variants, usually
identify only one functionally dominant key mutation per allele.
This possibly reduces the predictive power of genotyping for certain
haplotypes. The most comprehensive commercially available plat-
form for CYP2D6 genotyping is the AmpliChip CYP450 test from
Roche. This microarray has probes to identify 33 CYP2D6 alleles, in-
cluding most conﬁrmed variants responsible for absent or impaired
enzyme activity and seven gene duplications, as well as two
CYP2C19 variant alleles (Jain, 2005; de Leon et al., 2009; Rebsamen
et al., 2009).
4.4.4. Clinical impact of genetic variation
Numerous clinical studies document the clinical importance of the
CYP2D6 polymorphism for response and/or ADRs to agents that are
either inactivated or activated by this enzyme.
Several antiarrhythmic drugs including metoprolol, timolol,
propafenone and others are metabolically inactivated by CYP2D6,
leading to increased exposure and risk of adverse events for PMs/
IMs, although clinical effects are still controversial (Fux et al., 2005;
Darbar & Roden, 2006; Klotz, 2007; Mörike et al., 2008; Bijl et al.,
2009; Rau et al., 2009). Many antidepressants and antipsychotics
are substrates of CYP2D6 (Table 3) and oxidative metabolism usually
leads to their inactivation and consequently a risk of overexposure in
PMs/IMs and underexposure in UMs. Studies on clinical effects have
however not been unanimous, in part due to inherently problematic
dosing of these drugs. The area has been extensively reviewed
(Kirchheiner et al., 2004; Bertilsson, 2007; Crisafulli et al., 2011;
Stingl et al., 2012).
Several opioid drugs including codeine, dihydrocodeine, oxyco-
done, and tramadol used in pain management are metabolically acti-
vated by CYP2D6 and genotype was shown to affect their efﬁcacy and
safety (Stamer et al., 2010; Leppert, 2011; Madadi et al., 2012). The
prodrug codeine is O-demethylated by CYP2D6 to the pharmacologi-
cally active analgesic morphine. In CYP2D6 PMs there is no analgesic
effect due to extremely low morphine plasma concentrations
(Eckhardt et al., 1998). Conversely, increased effectiveness of codeine
with sometimes life-threatening opioid intoxication was observed in
patients with multiple CYP2D6 gene copies but also in neonates
whose breastfeeding mothers were genetic CYP2D6 UMs, consistent
with higher rates of conversion to morphine in patients with UM phe-
notype (Gasche et al., 2004; Koren et al., 2006; Madadi et al., 2009).
This scenario of morphine intoxication of neonates including further
glucuronidation via UGT2B7 has been the subject of a computerized
quantitative modeling study (Willmann et al., 2009). The physiologi-
cally based pharmacokinetic model was able to simulate the accumu-
lation of morphine in the plasma of neonates during maternal
codeine intake for different genotypes and to identify risk factors.
The selective estrogen receptor modulator (SERM) tamoxifen is
extensively metabolized into at least 22 metabolites, two of which,
4-hydroxytamoxifen and the secondary metabolite endoxifen, are
thought to be mainly responsible for the antiestrogenic effect because
of their high afﬁnity to the estrogen receptor (Johnson et al., 2004;
Mürdter et al., 2011b). Because CYP2D6 is the major enzyme for the
crucial 4-hydroxylation (Dehal & Kupfer, 1997; Coller et al., 2002;
Johnson et al., 2004), CYP2D6 genotype should be expected to inﬂu-
ence plasma concentrations of these active metabolites and hence
treatment outcome, with patients having functionally impaired
CYP2D6 producing lower levels of active metabolites and thusproﬁting less from the treatment compared to patients with active
enzyme (Brauch et al., 2009). This hypothesis has been scrutinized
over the past decade, and initial retrospective studies found indeed
that CYP2D6 PMs show less beneﬁt from adjuvant treatment of post-
menopausal breast cancer with tamoxifen monotherapy (Goetz et al.,
2007; Schroth et al., 2007). However, while several more recent stud-
ies conﬁrmed an association of CYP2D6 PM genotype with worse
outcome (Schroth et al., 2009; Kiyotani et al., 2010; Madlensky
et al., 2011) or demonstrated a beneﬁcial therapeutic effect of
genotype-guided treatment (Irvin et al., 2011; Kiyotani et al., 2012),
other studies found no (Rae et al., 2012; Regan et al., 2012) or incon-
sistent allele-speciﬁc effects (Abraham et al., 2010). Possible explana-
tions for inconsistent results include a number of confounding factors
that have not been taken into account systematically, including previ-
ous chemotherapy, enzyme inhibition due to co-medication, meno-
pausal status, but also differences in genotyping quality like limited
CYP2D6 allele coverage or use of tumor instead of germline DNA for
genotyping (see discussion comments by Brauch et al., 2013;
Nakamura et al., 2012; Pharoah et al., 2012; Stanton, 2012). Despite
existing evidence, well-planned prospective studies seem to be inev-
itable to clarify the real value of CYP2D6 predictive genotyping for
clinical utility.
A recent study investigated the chemically related SERM clomi-
phene, chemically closely related to tamoxifen, which is used as ﬁrst
line infertility treatment in women. Like tamoxifen, clomiphene is a
prodrug and requires bioactivation by 4-hydroxylation. CYP2D6 was
shown to be the key enzyme in the conversion of clomiphene to its
active metabolites (E)-4-hydroxy-clomiphene and (E)-4-hydroxy-
desethyl-clomiphene by human liver microsomes (Ghobadi et al.,
2008; Mürdter et al., 2011a). A strong gene-dose effect was found
for the formation rate of both metabolites in microsomes and in a
pharmacokinetic study including healthy women genotyped for
CYP2D6. Furthermore, both metabolites were shown to mediate clo-
miphene action through oestrogen receptor binding. Clinical studies
are therefore warranted to prove the validity of CYP2D6 genetics for
individualization of clomiphene therapy in infertility.
In addition the gene has been studied as a risk factor for numerous
diseases. Most of the epidemiological studies revealed conﬂicting
results concerning pharmacogenetic association and the reader is re-
ferred to specialized articles, for example, regarding Parkinson's dis-
ease (Christensen et al., 1998), schizophrenia and other psychiatric
diseases (Patsopoulos et al., 2005; Stingl et al., 2012), Alzheimer's dis-
ease (Scordo et al., 2006), and several forms of cancer (Agundez,
2004; Rodriguez-Antona et al., 2010).4.5. Subfamily CYP2E: CYP2E1
4.5.1. Regulation and variability of gene expression
CYP2E1 is the only gene of the CYP2E subfamily located at chromo-
some 10q26.3. Its expression is undetectable in fetal liver. Within sev-
eral hours after birth protein and activity rise considerably but
independently of mRNA which remains quite low (Vieira et al.,
1996). Stabilization of CYP2E1 protein by ketone bodies could explain
the early neonatal rise at the protein level. During the following pe-
riods from one month to one year, accumulation of CYP2E1 mRNA is
correlated with the methylation status of CpG residues in the 5′
ﬂanking region. Transcriptional activators suggested to participate
in the regulation of CYP2E1 expression include HNF1α and β-
catenin (Gonzalez, 2007). Expression in liver is rather high (Table 2)
and variability of CYP2E1 protein between individuals appears to be
considerable and correlated to catalytic activity (Ohtsuki et al.,
2012; Tan et al., 2001). One study reported one third greater clear-
ance values for the probe drug, chlorzoxazone, in males compared
to females (Kim & O'Shea, 1995). CYP2E1 transcript levels are not
well or not at all correlated to protein, and this has been suggested
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sion by miR-378 (Mohri et al., 2010).
The CYP2E1 enzyme is inducible by many of its substrates
(Table 3) as well as several hormones by complex mechanisms in-
volving transcriptional, translational and posttranslational effects
(Gonzalez, 2007). In humans induction by ethanol was shown to
involve increased transcription which primarily takes place in
perivenous hepatocytes (Takahashi et al., 1993). Signiﬁcant and
rapid induction of CYP2E1 activity was shown to occur already at
moderate alcohol consumption which was rapidly reversed following
alcohol withdrawal (Oneta et al., 2002). CYP2E1 is furthermore in-
duced under diverse pathophysiological conditions including diabe-
tes, obesity, fasting, alcohol and non-alcoholic liver disease where it
is believed to play a pathophysiological role (Caro & Cederbaum,
2004; Aubert et al., 2011). Extrahepatic expression of CYP2E1 has
been found at lower levels in brain, nasal mucosa, kidney cortex, tes-
tis, ovaries, the gastrointestinal tract and at somewhat higher levels in
cardiac tissue (Lieber, 1997; Joshi & Tyndale, 2006; Thelen &
Dressman, 2009; Michaud et al., 2010; Ferguson & Tyndale, 2011).
4.5.2. Role of CYP2E1 in drug metabolism and toxicology
CYP2E1 displays a substrate preference for low molecular weight
molecules, including ethanol, acetone and other organic solvents,
narcotics like halothane, and some drugs including chlorzoxazone
and paracetamol (Table 3). Many known industrial chemicals and oc-
cupational and environmental toxicants as well as procarcinogens are
also CYP2E1 substrates (Bolt et al., 2003; Lu & Cederbaum, 2008). En-
dogenous substrates of CYP2E1 are lauric acid and acetone, a product
of fatty acid oxidation, which is oxidized to acetol and further to
1,2-propanediol in the propanediol pathway of gluconeogenesis.
The role of CYP2E1 in ethanol oxidation depends on the conditions.
The major enzyme for ethanol oxidation to acetaldehyde is alcohol
dehydrogenase (ADH), whereas CYP2E1 plays a more important
role at elevated concentrations and after chronic consumption due
to induction (Caro & Cederbaum, 2004).
An important feature of ethanol oxidation via CYP2E1 is the gener-
ation of reactive oxygen species (ROS) which contributes to damage
of liver cells. CYP2E1 is an effective generator of ROS such as the su-
peroxide anion radical and hydrogen peroxide as a result of
uncoupling of oxygen consumption with NADPH oxidation (Caro &
Cederbaum, 2004). The fact that signiﬁcant levels of CYP2E1 are locat-
ed within the mitochondria could contribute further to its deleterious
effects (Knockaert et al., 2011). A number of studies therefore impli-
cated CYP2E1 as a causative player in alcoholic liver disease as well
as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) probably through enhancement of hepatic
lipid peroxidation (Cederbaum, 2006; Aubert et al., 2011). Further-
more, chronic alcohol consumption has been recognized as a major
risk factor for esophageal cancer, probably due to carcinogenic and
genotoxic effects of acetaldehyde and oxidative stress (Wang et al.,
2009; Millonig et al., 2011).
4.5.3. Genetic polymorphisms and pharmacogenetics
The CYPalleles website lists only 7 distinct CYP2E1 star-alleles and
few variants compared to other CYP2 genes, and for none of them
could an important functional impact be demonstrated. Some studies
suggested effects on expression for several 5′-upstream region poly-
morphisms, including an insertion of several repeats (CYP2E1*1D;
McCarver et al., 1998) and polymorphic PstI (−1293G>C) and Rsa
I (−1053C>T) sites (Neafsey et al., 2009; Tan et al., 2001). The latter
two polymorphisms occur together on alleles *5A and*5B, the latter of
which lacks an additional nucleotide change in intron 6 (7632T>A),
which can be detected as a DraI RFLP. CYP2E1*5A has an approximate
frequency 5% in Caucasians and up to 38% in Asians, whereas *5B ap-
pears to be present only in Asians at ~2 to 8% frequency. Only few
coding-region variants have been reported with little or no impacton enzyme function. A recent study analyzed 11 polymorphisms
and their haplotypes in over 2600 individuals from population sam-
ples representing the major geographical regions of the world (Lee
et al., 2008a). Similar to other genetic loci, CYP2E1 haplotype diversity
was much higher among African populations (6–10 common
haplotypes) than in other parts of the world (about 1–6 common
haplotypes).
Because of the particular relevance of CYP2E1 for toxicology due to
its role in the metabolic activation of procarcinogens and chemical
carcinogenesis, pharmacogenetic studies mostly focused on associa-
tion with various cancers. For example, genetic polymorphisms in
CYP2E1 have been associated with altered susceptibility to hepatic
cirrhosis induced by ethanol and with increased risk of development
of esophageal cancer and other malignant tumours. Likewise,
long-term intake of CYP2E1 inducers has also been recognized as a
risk factor for malignancy, in particular for carriers of certain variant
CYP2E1 alleles. As these studies are complex and often contradictory
in their results, the reader is referred to some recent specialized re-
views and meta-analyses on CYP2E1 and risk of chemically induced
cancers (Trafalis et al., 2010), association with lung cancer risk
(Wang et al., 2010b), and alcohol-related cancers (Druesne-Pecollo
et al., 2009).
4.6. Subfamily CYP2J: CYP2J2
4.6.1. Regulation and variability of gene expression
The human CYP2J subfamily has only a single gene, CYP2J2, which
encodes a 502 amino acid microsomal P450 protein. Like all other
CYP2 members, the CYP2J2 gene comprises 9 exons and 8 introns,
which are spread over a region encompassing about 40 kb on chro-
mosome 1. The CYP2J2 gene promoter lacks a TATA-box and its
basal activity is regulated predominantly by Sp1, for which at least
4 different binding sites are present within the ﬁrst 100 bp of 5′-up-
stream sequence (King et al., 2002). This promoter arrangement is
consistent with a “housekeeping” nature of this P450 gene, which
does not seem to be inducible by typical P450 inducers. CYP2J2 is
expressed at high levels in the heart, especially in cardiac myocytes
and in endothelial cells (Wu et al., 1996; Delozier et al., 2007;
Michaud et al., 2010), and at lower levels it is also expressed in
lung, gastrointestinal tract, and pancreas, as well as in selected brain
regions (Table 2). In the liver CYP2J2 abundance is less than 1% of
total P450 content, and similar estimations have been made regard-
ing expression in small intestine (Paine et al., 2006; Yamazaki et al.,
2006). Prenatal expression of CYP2J2 mRNA and protein was also ob-
served in these tissues (Gaedigk et al., 2006).
4.6.2. Role of CYP2J2 in drug metabolism and toxicology
The role of CYP2J2 in drug metabolism has not been fully evaluat-
ed. Several antihistamine drugs including terfenadine, ebastine, and
astemizole, have been identiﬁed as efﬁcient substrates but the contri-
bution of CYP2J2 to overall clearance is not clear andmay strongly de-
pend on the tissue (Table 3; Matsumoto et al., 2002; Laﬁte et al.,
2007). One recent study screened 139 marketed drugs from different
therapeutic classes and identiﬁed eight novel CYP2J2 substrates in-
cluding amiodarone, cyclosporine, and other drugs typically metabo-
lized by CYP3A4, however with different regioselectivity (Lee et al.,
2010).
CYP2J2 is one of the major P450 enzymes to metabolize arachidonic
acid (AA) predominantly via NADPH-dependent oleﬁn epoxidation to
20-HETE and all four regioisomeric cis-epoxyeicosatrienoic acids, i.e.
the 5,6-, 8,9-, 11,12-, and 14,15-EETs (Node et al., 1999; Xu et al.,
2011). These AA metabolites play important roles in the regulation
of renal, pulmonary, cardiac and vascular functions. In the heart some
of the CYP2J2-generated products have anti-inﬂammatory and
vascular-protective effects. For example the 11,12-EET exerts anti-
inﬂammatory effects by inhibiting endothelial nuclear factor-κB, a
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sponses in the vascular wall. The CYP2J2 products 8,9- and 11,12-EETs
were also shown to activate anti-inﬂammatory functions by binding
as ligands to PPARα (Wray et al., 2009).
Besides its cardioprotective functions, CYP2J2 is also being investi-
gated for its role in cancer as it was found to be highly and selectively
expressed in different human tumor tissues and cancer cell lines
(Chen et al., 2009). Interestingly, CYP2J2 inhibitors structurally relat-
ed to the drug terfenadine decreased EET production and inhibited
proliferation and neoplastic phenotypes of human tumor cells and
in murine xenograft models.
4.6.3. Genetic polymorphisms and pharmacogenetics
Considerable interindividual variation in CYP2J2 expression has
been observed and investigated in relation to genetic polymorphism.
The CYPalleles website lists 10 distinct star alleles, eight of which
carry nonsynonymous SNPs. Some of these variants (*2: T143A; *3:
R158C; *4: I192N; *6: N404Y) were shown to have decreased catalytic
activity towards AA when tested recombinantly in an insect cell sys-
tem (King et al., 2002). The signiﬁcance of these amino acid variants
for drug substrates of CYP2J2 has not been investigated, to our knowl-
edge. The most common CYP2J2 allele variant with functional
relevance is CYP2J2*7, which occurs at frequencies of ~2–17% in differ-
ent populations (Table 1). The key SNP rs890293 is located in the
proximal promoter at (−76G>T) and disrupts one of the SP1 binding
sites, which results in ~50% reduced promoter-activity relative to the
wild-type promoter (Spiecker et al., 2004). Because of the assumed
role of CYP2J2 in physiological processes of the heart, most
pharmacogenetic studies analyzed CYP2J2*7 in cohorts of patients
with coronary artery disease, coronary heart disease, myocardial
infarction, or hypertension. So far these studies did not result in con-
clusive associations, with many of them showing either no or contro-
versial associations (Berlin et al., 2011; Xu et al., 2011). The in vivo
relevance of CYP2J2 polymorphism thus remains to be established.
5. Family CYP3: CYP3A4, CYP3A5, CYP3A7, CYP3A43
5.1. Regulation and variability of gene expression
The human CYP3 family consists only of one subfamily, CYP3A, which
is located on chromosome 7q22.1 and has a size of 231 kb. It comprises
the four CYP genes 3A4, 3A5, 3A7, and 3A43. The mouse Cyp3a cluster
contains 7 full length genes but there are no orthologous pairs between
mouse and human, suggesting that a single CYP3A gene present in the
common ancestor existed, which independently expanded during the
last 75 MY (Nelson et al., 2004). CYP3A4 is in themajority of individuals
abundantly expressed in liver but population variability is extremely
high (>100-fold), although complete absence of expression has not
been deﬁnitively proven to our knowledge. Average microsomal
content has been estimated between ~60 pmol per mg of microsomal
protein (Ohtsuki et al., 2012) to 110 pmol/mg (Klein et al., 2012) to
~146 pmol/mg (Westlind-Johnsson et al., 2003), representing on aver-
age about ~14–24% to the microsomal P450 pool (Shimada et al.,
1994; Lin et al., 2002;Wolbold et al., 2003; Ohtsuki et al., 2012). Expres-
sion of the threeminor isoforms, CYP3A5, CYP3A7, and CYP3A43 is gen-
erally lower compared to CYP3A4, although the contribution of CYP3A5
in carriers of CYP3A5*1may be substantial in low expressors of CYP3A4
(Hustert et al., 2001; Kuehl et al., 2001; Koch et al., 2002;
Westlind-Johnsson et al., 2003; Daly, 2006). According to a recent
mass-spectrometric quantiﬁcation, the mean fractions of CYPs 3A4, 3A5,
3A7, and 3A43 proteins of the total microsomal CYP3A protein amount
measured in 17 adult samples were 85.4% (range, 6.2–270 pmol/mg),
5.4% (2.5–17.1), 3.4% (≤9.4), and 5.8% (≤6.4), respectively (Ohtsuki et
al., 2012). If one sample with high CYP3A5 expression (genotype was
not determined) was omitted, CYP3A5 expression ranged from 2.5 to
4.3 pmol/mg. CYP3A7 is more abundantly expressed in fetal liver thanin adult liver but the mechanism for this has not been studied in detail
(Cresteil, 1998; Leeder et al., 2005). CYP3A4 is the major expressed
P450 in intestinal enterocytes, with levels uncorrelated to those of liver,
and contributes substantially to the ﬁrst-pass metabolism of orally ad-
ministered drugs (Ding & Kaminsky, 2003; von Richter et al., 2004a;
Daly, 2006). In other extrahepatic tissues including the respiratory tract,
brain, lung, and kidney, CYP3A5 expression appears to be predominant
or similar to CYP3A4 (Table 2; Raunio et al., 2005; Daly, 2006; Dutheil
et al., 2008; Pavek & Dvorak, 2008; Bolbrinker et al., 2012). Multiple sig-
naling pathways contribute to the complex regulation of the CYP3A
genes. Constitutive transcriptional regulation includes both positive and
negative regulators, in particular C/EBPα and C/EBPβ (Jover et al., 2002;
Rodriguez-Antona et al., 2003; Martinez-Jiménez et al., 2005), HNF1α
and HNF3γ (Rodriguez-Antona et al., 2003), HNF4α (Tirona et al., 2003;
Tegude et al., 2007; Jover et al., 2009), and USF (Biggs et al., 2007). Induc-
ible transcriptional regulation in response to numerous xenobiotics
(Table 3) is due to at least three major cis-acting modules: the proximal
PXR responsive element prPXRE, the distal (−7.2 to −7.8 kb)
xenobiotic-responsive enhancer module XREM, and the constitutive
liver enhancer module CLEM4 (−11.4 to −10.5 kb; Matsumura et al.,
2004; Jover et al., 2009; Qiu et al., 2010). The xenosensors PXR and
CAR,which bind to these regions, translocate to the nucleus uponbinding
of structurally diverse drug ligands, including barbiturates, rifampicin,
statins, and many other drugs and then heterodimerize with RXR to en-
hance transcription several-fold (Timsit & Negishi, 2007; Liu et al.,
2008; Pascussi et al., 2008). These nuclear receptors were also shown to
induce CYP3A5 in liver and intestine (Burk et al., 2004), which explains
the observed coregulation between hepatic CYP3A4 and CYP3A5 (Lin
et al., 2002). Additional ligand-dependent transcriptional regulators of
CYP3A4 include the bile acid receptor FXR (Gnerre et al., 2004), the glu-
cocorticoid receptor (Pascussi et al., 2008), the oxysterole receptor LXR
(Duniec-Dmuchowski et al., 2007), and the vitamin D receptor
(Matsubara et al., 2008). Recent studies indicate that PPARα also contrib-
utes to constitutive and inducible regulation of CYP3A4. In a genetic can-
didate gene approach (see below), PPARα SNPs were found to affect
hepatic CYP3A4 phenotypes including atorvastatin hydroxylase activity
(Klein et al., 2012) and in a systems biology approach genome-wide
time-resolved data from human hepatocytes challenged with statins
identiﬁed, among others, PPARα as an inﬂuential factor for CYP3A4
expression (Schröder et al., 2011). Validation experiments in these stud-
ies demonstrated ~3-fold induction of CYP3A4 in human hepatocytes by
the potent PPARα agonist, WY14,643, while the antagonist MK886
and shRNA-mediated PPARα knock-down lead to marked repression.
These studies together with an earlier transcriptional proﬁling study
(Rakhshandehroo et al., 2009) clearly demonstrate an impact of the
lipid homeostase regulator PPARα on CYP3A4.
Also of considerable importance is cytokine-mediated down-
regulation of CYP3A4 in the course of the inﬂammatory response via
JAK/STAT pathway (Jover et al., 2002). This is clinically relevant for ex-
ample in cancer patients because tumors can be a source of systemically
circulating cytokines which then lead to substantial down-regulation of
CYP3A4 and other drug metabolizing enzymes and transporters
(Slaviero et al., 2003; Aitken et al., 2006). Moreover, as summarized in
chapter 3.3, CYP3A4 shows signiﬁcant activity and expression differ-
ences in females versus males (Wolbold et al., 2003; Cotreau et al.,
2005; Lamba et al., 2010). Recently, higher activity in females was
also conﬁrmed in women from Tanzania (Pb0.001) and Korea
(Pb0.00001) by measuring the proposed endogenous CYP3A4/5
metabolite-marker 4β-hydroxycholesterol (Diczfalusy et al., 2011).
The mechanistic basis for sex-biased expression of CYP3A4 and other
CYPs has not been elucidated but may involve different growth
hormone/Stat5b signaling (Waxman&Holloway, 2009). A recent inves-
tigation in human hepatocytes from female and male donors found
more efﬁcient hormone-dependent activation, greater extent of nuclear
translocation, and stronger binding to DNAmotifs of HNF4α and PXR in
female compared to male hepatocytes (Thangavel et al., 2011).
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The CYP3A subfamily enzymes play a major role in the metabo-
lism of ~30% of clinically used drugs from almost all therapeutic cate-
gories (Fig. 1; Table 3; Bu, 2006; Liu et al., 2007; Zanger et al., 2008).
The active site of CYP3A4 is large and ﬂexible and can accommodate
and metabolize many preferentially lipophilic compounds with com-
paratively large structures (Scott & Halpert, 2005; Hendrychová et al.,
2011). Typical large substrates are immunosuppressants like cyclo-
sporin A and tacrolimus, macrolide antibiotics like erythromycin,
and anticancer drugs including taxol, but smaller molecules are also
accepted including ifosfamide, tamoxifen, benzodiazepines, several
statins, antidepressants, opioids and many more (Table 3). CYP3A4
is also an efﬁcient steroid hydroxylase with an important role in the
catabolism of several endogenous steroids including testosterone,
progesterone, androstenedione, cortisol and bile acids. Although sev-
eral probe drugs that measure general CYP3A activity are available,
e.g. midazolam, erythromycin, alprazolam, and dextromethorphan
(Fuhr et al., 2007; Liu et al., 2007), phenotyping data obtained with
different CYP3A substrates are not generally well correlated to each
other, a CYP3A4-typical feature that may be related to the occurrence
of several overlapping substrate binding regions and the well-known
allosteric regulation of CYP3A4 enzyme activity (Niwa et al., 2008;
Foti et al., 2010; Roberts et al., 2011).
The high sequence similarity between the CYP3A isozymes (CYP3A4
and CYP3A5 share>85%primary amino acid sequence identity) leads to
highly similar substrate selectivity between the isoforms (Williams et
al., 2002). Nevertheless, some limited substrate and regioselectivity
differences were observed. For example, aﬂatoxin B1 (AFB1) 3α-
hydroxylation to AFQ1 is solely catalyzed by CYP3A4 and results in
detoxiﬁcation and subsequent elimination of AFB1, whereas CYP3A5
converts it to the genotoxic exo-8,9-epoxide AFBO (Kamdem et al.,
2006). Another example is the aromatic ortho-hydroxylation of atorva-
statin, which is 16-fold more efﬁciently catalyzed by CYP3A4 compared
to CYP3A5 (Feidt et al., 2010).
5.3. Genetic polymorphisms and functional impact
5.3.1. CYP3A4
Drug oxidation phenotypes of CYP3A4 are strongly variable but
unimodally distributed. Nevertheless there is indication of substantial
heritability. For example, antipyrine 4-hydroxylation rate, which is
mainly catalyzed by CYP3A4 (Engel et al., 1996), was reported to be
largely inherited as shown in early twin studies (Penno et al., 1981).
Moreover, a repeated drug administration approach lead Kalow and
colleagues to conclude a high degree of heritability for CYP3A4 drug
oxidation capacity towards several of its substrates (Ozdemir et al.,
2000). The genetic basis for these observations remained obscure
even though several resequencing and haplotype tagging studies
have recently been carried out at the CYP3A locus in ethnically diverse
populations (Thompson et al., 2006; Schirmer et al., 2007; Perera et
al., 2009; Perera, 2010). A genome-wide association study carried
out in 310 twins, who had been induced with St John's Wort, also
failed to identify signiﬁcant associations (Rahmioglu et al., 2012).
The apparent “missing heritability” of CYP3A4 drug oxidation pheno-
type is thus an intriguing genetic problem (Sadee, 2012).
One of the more common and frequently studied polymorphisms
is the proximal promoter variant CYP3A4*1B [-392A>G] which occurs
in white populations at ~2 to 9% but at higher frequencies in Africans
(Table 1). This SNP was initially found to be associated with higher
tumor grade and stage in prostate cancer and showed higher nifedi-
pine oxidase activity in human livers (Rebbeck et al., 1998). Associa-
tion of CYP3A4*1B with markers of advanced disease was conﬁrmed
by some but not all further studies (Keshava et al., 2004; Perera,
2010). A functional effect of this variant could however not be
established and remained controversial, despite several studies invitro and in human liver (Wandel et al., 2000; Spurdle et al., 2002;
Rodríguez-Antona et al., 2005; Klein et al., 2012).
A notable recent discovery is the intron 6 C>T variant rs35599367
(CYP3A4*22) which was found by a systematic screen for SNPs show-
ing allelic expression imbalance in human liver and with decreased
mRNA expression in cultured cells transfected with minigenes
(Wang et al., 2011). These authors found that the effect of the variant
was not confounded by sex or other variables and that it accounted
for 7% of the mRNA expression variability in a cohort of 93 liver sam-
ples. In another recent liver study this variant was associated with de-
creased protein levels by univariate and multivariate analysis (Klein
et al., 2012).
Another intronic variant rs4646450, located in the CYP3A5 gene,
has recently been associated with reduced tacrolimus dosage require-
ment in Japanese patients (Onizuka et al., 2010) and with reduced
serum dihydroepiandrosterone sulfate concentrations (Zhai et al.,
2011). This variant was also associated with decreased protein and
activity of CYP3A4 in human liver, explaining about 3–5% of hepatic
variability (Klein et al., 2012). This indicates that SNPs at the CYP3A
locus exist that are likely to inﬂuence expression, and possibly there
are more to be discovered.
Another possibility to explain the “missing heritability” of CYP3A4
variability is that polymorphic trans-acting genetic factors could ac-
count in part. Initial studies indicated that PXR variants may contribute
to CYP3A4 expression differences (Lamba et al., 2005, 2008). Recently
this hypothesis was explored more systematically using liver tissue
banks. Several genome-wide association studies with a total number
of >800 human liver samples failed however to identify novel signiﬁ-
cant markers of CYP3A4 expression and function (Schadt et al., 2008;
Yang et al., 2010; Innocenti et al., 2011; Schröder et al., 2013; Glubb et
al., 2012). This disappointing result is probably due to lack of power
due to the statistical correction for the large number of tests. In contrast,
two recent studies applied candidate-gene approaches to detect cis-
and trans-SNPs inﬂuencing expression phenotypes. Lamba and col-
leagues phenotyped 128 livers by quantitative real-time PCR for
expression of CYP3A genes and identiﬁed a functional CCT-repeat poly-
morphism in the FoxA2 gene to be associated with higher expression of
FoxA2mRNA and its targets PXR and CYP3A4 (Lamba et al., 2010). Poly-
morphisms in FoxA2, HNF4α, FoxA3, PXR, ABCB1, and the CYP3A4 pro-
moter together explained 24.6% of the variation in hepatic CYP3A4
mRNA expression. However the study lacked information of the rele-
vance of these variations for CYP3A4 protein and activity.
In a liver cohort study mentioned earlier, Klein and colleagues
phenotyped 149 Caucasian liver samples for CYP3A4mRNA and protein
levels and for verapamil N-demethylase and atorvastatin hydroxylase
activities (Klein et al., 2012). They identiﬁed SNPs in the Ah-receptor
nuclear translocator (ARNT), glucocorticoid receptor (GR), progesterone
receptor membrane component 2 (PGRMC2), and peroxisome
proliferator activated receptor alpha (PPARα) to be consistently associ-
ated with CYP3A4 phenotype. Validation in an atorvastatin-treated
volunteer cohort conﬁrmed decreased atorvastatin-2-hydroxylation in
carriers of PPARα SNP rs4253728. Moreover, homozygous carriers
expressed signiﬁcantly less PPARα protein in liver and shRNA-
mediated PPARα gene knock-down in primary human hepatocytes de-
creased expression levels of CYP3A4 by more than 50%. Multivariate
analysis revealed that two linked PPARα SNPs alone explained ~8–9%
of the atorvastatin hydroxylase activity variation, whereas all genetic
and nongenetic factors together accounted for ~33% of atorvastatin
2-hydroxylase variation (Klein et al., 2012).
5.3.2. CYP3A5
Expression of CYP3A5 in liver is polymorphic as only a fraction of
about 5 to 10% of Caucasians, but 60% or more of Africans or African
Americans have appreciable amounts expressed in their liver. These
ethnic differences are largely explained by two alleles that result in
aberrant splicing and deﬁcient expression of the functional transcript.
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tron 3 that leads to aberrant splicing and a truncated protein, and oc-
curs in all ethnic groups studied, with large frequency differences
between major races (Table 1; Kuehl et al., 2001). CYP3A5*6 with an
exon 7 mutation that also leads to an aberrantly spliced mRNA lack-
ing exon 7 was only detected in populations of African origin (Kuehl
et al., 2001; Roy et al., 2005). Another null allele, CYP3A5*7, includes
a frame-shift mutation (Hustert et al., 2001). Taken together, only a
small percentage of Caucasian subjects but considerably larger frac-
tions of Asians and Africans have a functional copy of the CYP3A5
gene (*1). In these individuals, CYP3A5 could make a signiﬁcant con-
tribution to drug metabolism, particularly for substrates with prefer-
ential metabolism by CYP3A5 over CYP3A4 (e.g., tacrolimus) and in
individual with a low expression of CYP3A4.
5.3.3. CYP3A7
The fetal-predominant form accounts for up to 50% of total P450
content in fetal livers (Cresteil, 1998; Leeder et al., 2005). Although
expression shifts after birth from CYP3A7 to CYP3A4, it remains poly-
morphically expressed in some adult livers and in intestine (Burk et
al., 2002). Most of the CYP3A7 mRNA high expressor phenotypes
could be explained by the CYP3A7*1C promoter variant, which har-
bors a recombined promoter starting with –188G>T and extending
to−129, which has been replaced by the corresponding CYP3A4 pro-
moter from −210 to −250 bp. The mutant gene is more effectively
transcribed due to increased binding and transactivation by HNF4α,
PXR/RXR and CAR/RXR heterodimers to a polymorphic ER6 motif
(Burk et al., 2002). Further studies with a speciﬁc antibody estimated
the relative content of CYP3A7 to the total CYP3A pool to be between
9 and 36% for the ~10% of high expressors and about 10-fold lower in
the low expressors (Sim et al., 2005). Additional alleles of the CYP3A7
gene can be found on the CYPalleles website. Due to the large overlap
in substrate speciﬁcity with other CYP3A enzymes the clinical signif-
icance CYP3A7 polymorphism has not been well studied.
5.4. Clinical impact of genetic variation
5.4.1. CYP3A4
In agreement with a decreasing effect of the *22 variant on CYP3A4
expression, patients treatedwith atorvastatin, simvastatin, or lovastatin
who were carriers of the T allele required 1.7- to 5-fold reduced statin
doses compared to non-T carriers for optimal lipid control (Wang et
al., 2011). Signiﬁcant association of CYP3A4*22 with decreased
2-OH-atorvastatin/atorvastatin AUC0–∞ ratio was observed in
atorvastatin-treated volunteers (Klein et al., 2012). The association of
CYP3A4*22 with simvastatin lipid-lowering response was also shown
in another clinical study (Elens et al., 2011a). Furthermore, renal trans-
plant recipients who were carriers of the low-expressor T-allele had
a 33% reduced mean daily-dose requirement to reach the same
tacrolimus blood concentration compared to homozygotes for the
wild type allele (Elens et al., 2011b) and 1.6 to 2.0-fold higher
dose-adjusted trough blood levels of tacrolismus and cyclosporine in
stable renal transplant patients (Elens et al., 2011c). Despite these con-
sistent reports, the rather low frequency of this intron 6 variant (global
minor allele frequency 2.1%, Caucasians 3–8%; Table 1) limits its contri-
bution to overall CYP3A4 variability.
5.4.2. CYP3A5
Associations with CYP3A5 genotype were reported, for example,
for the immunosuppressant tacrolimus (Hesselink et al., 2003;
Anglicheau et al., 2007; Elens et al., 2011b); the antihypertensive ve-
rapamil (Jin et al., 2007), and the HIV protease inhibitor saquinavir
(Josephson et al., 2007). Tacrolimus-related nephrotoxicity is clinical-
ly highly relevant and dose adjustment of tacrolimus by therapeutic
drug monitoring is common clinical practice in renal transplant pa-
tients as recommended by the European consensus conference report(Wallemacq et al., 2009). To elucidate underlying mechanisms sever-
al studies investigated the contribution of CYP3A5 genetics demon-
strating a strong association between the deﬁcient allele CYP3A5*3
and lower tacrolimus clearance, higher blood concentrations, and
lower dose requirements (Staatz et al., 2010a, 2010b). In a large co-
hort of ‘real-world’ kidney transplant recipients (n=446) on
tacrolimus steady state concentrations, CYP3A5*3 alone explained
39% of the variability of tacrolimus blood concentration to dose
(C/D) ratio, compared to 46% explained by clinical covariates and
CYP3A5*3 together (Birdwell et al., 2012). In another trial a predictive
model that included age, ethnicity and concomitant use of medica-
tions explained ~30% of the variability in tacrolimus dosing, which in-
creased to 58% by including CYP3A5*3 genotype (Wang et al., 2010c).
Thus, clinical variables and CYP3A5 pharmacogenetics explain ap-
proximately one-half of the interindividual variability in tacrolimus
C/D ratio, suggesting that algorithms for pharmacogenetics-guided
tacrolimus dosing should be helpful for clinical practice.
6. NADPH:cytochrome P450 oxidoreductase (POR)
NADPH:cytochrome P450 oxidoreductase (POR) is a microsomal
ﬂavoprotein which constitutes an essential component of several ox-
ygenase enzyme complexes including heme oxygenase, squalene
monooxygenase, 7-dehydrocholesterol reductase, and in particular
all 50 microsomal cytochrome P450 (CYP) monooxygenases. The
FMN/FAD ﬂavogroups of the protein mediate the transfers of two sin-
gle electrons originating from NADPH to the P450 prosthetic heme
iron. Furthermore, POR can directly metabolize a number of drugs
by 1-electron reduction reactions. This is particularly the case for
drugs with quinone moieties, including several anticancer prodrugs
such as menadione, mitomycin C, tirapazamine, and E09 used for
the treatment of solid tumors (Hart et al., 2008).
In contrast to the multiplicity of CYPs, mammals have only a single
POR gene. In humans the gene is located on chromosome 7q11.2 and
spans about 72 kb, coding for a 680 amino acid proteinwhichusesﬂavin
adenine dinucleotide (FAD) and ﬂavin mononucleotide (FMN) as pros-
thetic groups. Complete deletion of the por gene in mouse is embryoni-
cally lethal most likely due to deﬁcient adrenocortical steroidogenesis
(Shen et al., 2002; Otto et al., 2003). In contrast, liver-speciﬁc knockout
of por leads to phenotypically and reproductively normal mice that ac-
cumulate hepatic lipids and have a drastically diminished capacity for
hepatic drug metabolism (Gu et al., 2003; Finn et al., 2007).
The amount of POR in human liver is stoichiometrically ~5 to 10-fold
lower compared to themicrosomal CYP pool, raising the possibility that
it represents a limiting factor for monooxygenase function (Hart et al.,
2008; Gomes et al., 2009). Although interindividual variability of
POR expression in human liver is lower compared to most drug metab-
olizingmicrosomal CYP enzymes, it was shown to be signiﬁcantly corre-
lated to several CYP monooxygenase activities, supporting a possible
rate-limiting role in catalysis (Backes & Kelley, 2003). POR expression
variability is in part due to the inducibility of the POR gene by both
PXR and CAR (Maglich et al., 2002), as well as hormonal inﬂuences on
transcription (Tee et al., 2011), whereas other nongenetic factors in-
cluding sex, age, smoking and drinking habits do not appear to be of sig-
niﬁcant inﬂuence in liver (Hart et al., 2008; Gomes et al., 2009).
Following the discovery of an untranslated ﬁrst exon, the human POR
promoter was located and binding of transcription factors Smad3/
Smad4, as well as thyroid hormone receptor TRα and TRβ was con-
ﬁrmed by chromatin immunoprecipitation (Tee et al., 2011).
In recent years rare POR missense mutations in humans were dis-
covered that cause disordered steroidogenesis, ambiguous genitalia,
and Antley–Bixler syndrome (Flück et al., 2004; Huang et al., 2005;
Flück et al., 2008). The CYPalleles website currently lists 41 distinct
star-alleles, most of which represent vary rare variants identiﬁed in
patients with clinical manifestations of POR deﬁciency (Sim et al.,
2009). The causative mutations in these alleles either result in
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ous splicing or translation. The clinical and developmental aspects of
these rare POR variants have been recently reviewed (Flück & Pandey,
2011).
Using a cocktail phenotyping approach in a family with genetic
POR deﬁciency, subnormal activities of CYP1A2, CYP2C9, CYP2D6
and CYP3A4 were observed in a heterozygous patient with congenital
adrenal hyperplasia, demonstrating that POR activity can be limiting
in vivo at least for these P450 enzymes (Tomalik-Scharte et al., 2010).
Common POR polymorphisms also exist in addition to the rare
disease-causing mutations (Huang et al., 2005, 2008a). In particular
a A503V variation (POR*28) is present at high frequencies ranging
from 19% to 37% in all major ethnicities and has been studied most
extensively (Table 1). In a recombinant system the variant retained
>50% of the wild type activity towards several CYPs (Huang et al.,
2008b; Sandee et al., 2010), while in an analysis of 150 human liver
microsome samples it was not associated with signiﬁcant changes
in any of 11 measured CYP activities (Gomes et al., 2009). Neverthe-
less an in vivo study found that POR*28 TT genotype was associated
with a 1.6-fold increase in CYP3A midazolam 1′-hydroxylase activity
compared with POR*28 C carriers, a ﬁnding that could be replicated
in an independent cohort (Oneda et al., 2009). Similarly, in a cohort
of allograft recipients under tacrolimus therapy, POR*28 T-allele car-
riers had signiﬁcantly higher tacrolimus dose requirements compared
to noncarriers but only if they were genotypic CYP3A5 expressors (i.e.
presence of at least one CYP3A5*1 allele; (De Jonge et al., 2011). Thus,
the effect of this common POR variant appears to depend on both CYP
and substrate analyzed.
Numerous additional missense mutants that inﬂuence P450 activ-
ities in a CYP- and substrate speciﬁc manner have been identiﬁed
more recently (Hart et al., 2008; Huang et al., 2008a; Kranendonk et
al., 2008; Marohnic et al., 2010). In a large scale sequencing study,
Miller and colleagues sequenced the POR gene in 842 normal persons
from 4 ethnic groups and detected 140 SNPs of which 43 occurred at
>1% frequency and 13 were novel nonsynonymous variants (Huang
et al., 2008a). Moreover, polymorphisms in the promoter and in in-
trons could affect transcription and/or splicing, but have not yet
been investigated systematically. In the above-mentioned study,
twelve promoter variants were detected. One polymorphism at –
152 bp was described to result in decreased transcription in cell
lines (Tee et al., 2011). In addition, two common 5′-ﬂanking region
SNPs (−173C>A, -208C>T) and the intron 2 SNP rs2868177 were
signiﬁcantly associated with variations in warfarin maintenance
dose, in addition to several known factors, in a study of 122 male pa-
tients, who had attained a stable warfarin dose. A study in human
liver microsomes identiﬁed three intronic POR variants that affected
several CYP activities as determined by multivariate analysis, in con-
cert with the donor's sex (Gomes et al., 2009). An effect of intron 11
variant rs2302429G>A on CYP1A2 activity but not inducibility was
recently demonstrated in an in vivo study (Dobrinas et al., 2012).
Taken together these recent advances indicate that POR variants are
a complex but potentially relevant source of genetic variation for
steroid hydroxylation and drug oxidation (Miller et al., 2011).7. Conclusions and future perspectives
The scientiﬁc literature cited in this review, and many more articles
we could not mention, demonstrate the tremendous progress that has
been made in understanding the drug metabolizing cytochromes P450
with respect to their functional properties and differences, regulation
of gene expression, population variability, genotype–phenotype corre-
lation, and clinical impact. Regulation of all CYPs is clearlymultifactorial
with sex, age, hormonal and disease states and inhibition or induction-
type drug–drug interactions contributing to inter- and intraindividual
variability. Nevertheless, genomic markers have a conﬁrmed impacton several CYPs, approximately in the order CYP2D6>CYP2C19~
CYP2A6>CYP2B6>CYP2C9>CYP3A4/5.
Future directions should include basic as well as clinical aspects. In
basic research it will be interesting to see how many rare mutations
exist in these genes in various populations, and what their contribu-
tion to the total variability is. In this review we focused on common
variants, but because rare variants often have stronger impact on
phenotype, their collective role for complex phenotypes may be sig-
niﬁcant. Rare variants with strongly decreased function can be partic-
ularly important for phenotype if present in combination with
another allele or haplotype of moderately decreased function, as
shown for example in the case of efavirenz-treated HIV patients
(Rotger et al., 2007). Although earlier studies have shown that
genotyping of only few common variants is sufﬁcient to predict the
major phenotypes (Sachse et al., 1997; Griese et al., 1998), it should
be remembered that even in the case of CYP2D6 this conclusion was
based on very few probe drugs (i.e. debrisoquine, sparteine) that
have no clinical signiﬁcance today. For other substrates the situation
may be different.
Current progress in the 1000-genomes project and by targeted
re-sequencing suggests that the number of unknown rare polymor-
phisms and “private” mutations can make signiﬁcant contributions
to interindividual as well as interethnic variability, because these
mostly unknown variants show increased population-speciﬁcity and
are enriched for functional variants (Gamazon et al., 2009; Marth et
al., 2011; MacArthur et al., 2012). However, the task is a difﬁcult
one, because available in vitro test systems for CYP enzyme and
gene variants are time-consuming and unreliable and in vivo testing
on the other hand is impractical due to the low SNP frequencies. In
silico prediction tools to ﬁlter out potentially functional SNPs for fur-
ther study may thus be a promising approach, although functional ef-
fects of intronic and promoter variants remain especially difﬁcult to
predict (Pang et al., 2009).
Polymorphisms in trans-acting genes, for example genes that in-
ﬂuence monooxygenase activity (e.g., NADPH:cytochrome P450 re-
ductase, cytochrome b5) or in the numerous regulatory genes
involved in transcriptional, posttranscriptional and posttranslational
regulation have only been occasionally investigated so far but these
studies have shown potential to develop predictive multigenetic
gene signatures for CYP1A2 (Klein et al., 2010) and CYP3A4 (Klein
et al., 2012; Lamba et al., 2010). Furthermore, the contribution of
CNVs for drug metabolic phenotypes has also not been evaluated in
a systematic way, although several examples with functional impact,
including CYPs 2A6 and 2D6, as well as several phase II genes are
known (Johansson & Ingelman-Sundberg, 2008; Gamazon et al.,
2011). These directions may ultimately reveal the true genetic contri-
bution to variable CYP-dependent drug metabolism phenotype.
Concerning clinical aspects, it must be noted that translation of
this knowledge into clinical practice has been slow and not on a
broad front. The reasons for this are manifold and mostly not directly
related to P450 research but rather to organizational, medical, ethical
and legal issues which have been discussed in other reviews (Frueh &
Gurwitz, 2004; Woelderink et al., 2006; Pirmohamed, 2009; Lunshof
& Gurwitz, 2012). Future directions should focus on the proper eval-
uation of clinical outcomes and properly designed clinical studies to
assess the clinical utility as well as practicality of CYP genotyping. A
pharmacogenetic test is considered clinically useful when it can be
shown to improve drug therapy in terms of efﬁcacy or safety, whereas
practicality requires development of a suitable infrastructure, includ-
ing testing facility, instructed personel, and incorporation into the
general health care system. It is further necessary to realize that CYP
genotyping alone can not be the answer. For each drug, the relevant
genes have to be deﬁned and tested, along with other factors (sex,
age, health and nutritional condition, and many more), in order to ex-
ploit the full potential of pharmacogenetics for drug therapy. Systems
biology approaches, in particular physiology-based pharmacokinetic
131U.M. Zanger, M. Schwab / Pharmacology & Therapeutics 138 (2013) 103–141and pharmacodynamic modeling of the complex interplay between
the many levels and facets of drug-organism interactions should
also be expected to make major contributions in the future towards
implementing pharmacogenetic testing in personalized medicine
(Rostami-Hodjegan & Tucker, 2007; Eissing et al., 2011; Holzhütter
et al., 2012).
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